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Control Of Systemic Lipid Metabolism By Adipocyte Mtor Signaling
Abstract
Pharmacological agents targeting the mTOR complexes are used clinically as immunosuppressants and
anticancer agents, and can extend lifespan in model organisms. An undesirable side effect of these drugs
is hyperlipidemia. Raptor and Rictor are essential component of mechanistic target of rapamycin (mTOR)
complex 1 (mTORC1) and 2 (mTORC2), respectively. Despite multiple roles that have been described for
mTOR complex 1 (mTORC1) in lipid metabolism, the etiology of hyperlipidemia remains incompletely
understood. The objective of this study was to determine the influence of adipocyte mTORC1 signaling in
systemic lipid homeostasis in vivo. We characterized systemic lipid metabolism in mice lacking the
mTORC1 subunit raptor (RaptoraKO), the key lipolytic enzyme ATGL (ATGLaKO), or both (ATGLRaptoraKO) in adipocytes. Mice lacking mTORC1 activity in adipocytes failed to completely suppress
lipolysis in the fed state and displayed prominent hypertriglyceridemia and hypercholesterolemia.
Blocking lipolysis in adipose tissue restored normal levels of triglycerides and cholesterol in the fed state,
as well as the ability to clear triglycerides in an oral fat tolerance test. Unsuppressed adipose lipolysis in
the fed state interferes with triglyceride clearance and contributes to hyperlipidemia. Adipose tissue
mTORC1 activity is necessary for appropriate suppression of lipolysis and for the maintenance of
systemic lipid homeostasis. Loss of mTORC1 signaling in adipose is sufficient to disrupt lipid
homeostasis, resulting in hyperlipidemia caused by unrestrained lipolysis. However, studies to date
examining the role of deletion of this complex, complex 2 or both in adipose tissue in combination with
rapamycin have yet to be investigated. Here, we report the consequences of Raptor, Rictor or both deleted
specifically in mature adipocytes driven by Adiponectin-Cre (RaptoraKO, RictoraKO, Raptor-RictoraKO).
Concordant with the RaptoraKO mice, RictoraKO mice display pronounced hyperlipidemia and both KO
models have a further increase in plasma lipids with rapamycin treatment. Genetic inhibition of lipolysis in
mice with loss of mTORC1 (ATGL-RaptoraKO) treated with rapamycin prevents the further increase in
plasma lipids seen in Raptorako mice treated with rapamycin. We propose a hypothetical mechanism that
in the fed state, rapamycin inhibition of adipose mTORC1 leads to decreased C/EBP transcriptional
activity. This decreased transcriptional activity results in decreased expression of perilipin and
subsequent unrestrained lipolysis, leading to hyperlipidemia. Here we show that enhanced lipolysis upon
refeeding increases plasma triglyceride levels in the context of rapamycin treatment and that both
complexes are involved in regulating this lipolytic process. However, mTORC1, not mTORC2, is required
for proper adipocyte lipolysis to maintain circulating plasma lipid levels. Additionally, we provide evidence
that loss of adipocyte mTOR signaling is not solely responsible for the rapamycin induced hyperlipidemia.
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ABSTRACT
CONTROL OF SYSTEMIC LIPID METABOLISM BY ADIPOCYTE MTOR SIGANLING
Lauren M. Paolella
Joseph A. Baur, Ph.D.

Pharmacological agents targeting the mTOR complexes are used clinically as
immunosuppressants and anticancer agents, and can extend lifespan in model
organisms. An undesirable side effect of these drugs is hyperlipidemia. Raptor and
Rictor are essential component of mechanistic target of rapamycin (mTOR) complex 1
(mTORC1) and 2 (mTORC2), respectively. Despite multiple roles that have been
described for mTOR complex 1 (mTORC1) in lipid metabolism, the etiology of
hyperlipidemia remains incompletely understood. The objective of this study was to
determine the influence of adipocyte mTORC1 signaling in systemic lipid homeostasis in
vivo. We characterized systemic lipid metabolism in mice lacking the mTORC1 subunit
raptor (RaptoraKO), the key lipolytic enzyme ATGL (ATGLaKO), or both (ATGL-RaptoraKO)
in adipocytes. Mice lacking mTORC1 activity in adipocytes failed to completely suppress
lipolysis in the fed state and displayed prominent hypertriglyceridemia and
hypercholesterolemia. Blocking lipolysis in adipose tissue restored normal levels of
triglycerides and cholesterol in the fed state, as well as the ability to clear triglycerides in
an oral fat tolerance test. Unsuppressed adipose lipolysis in the fed state interferes with
triglyceride clearance and contributes to hyperlipidemia. Adipose tissue mTORC1
activity is necessary for appropriate suppression of lipolysis and for the maintenance of
systemic lipid homeostasis. Loss of mTORC1 signaling in adipose is sufficient to disrupt
lipid homeostasis, resulting in hyperlipidemia caused by unrestrained lipolysis. However,
studies to date examining the role of deletion of this complex, complex 2 or both in
adipose tissue in combination with rapamycin have yet to be investigated. Here, we
report the consequences of Raptor, Rictor or both deleted specifically in mature
adipocytes driven by Adiponectin-Cre (RaptoraKO, RictoraKO, RaptorRictoraKO). Concordant with the RaptoraKO mice, RictoraKO mice display pronounced
hyperlipidemia and both KO models have a further increase in plasma lipids with
rapamycin treatment. Genetic inhibition of lipolysis in mice with loss of mTORC1 (ATGLRaptoraKO) treated with rapamycin prevents the further increase in plasma lipids seen in
Raptorako mice treated with rapamycin. We propose a hypothetical mechanism that in the
fed state, rapamycin inhibition of adipose mTORC1 leads to decreased C/EBPa
transcriptional activity. This decreased transcriptional activity results in decreased
expression of perilipin and subsequent unrestrained lipolysis, leading to hyperlipidemia.
Here we show that enhanced lipolysis upon refeeding increases plasma triglyceride
levels in the context of rapamycin treatment and that both complexes are involved in
regulating this lipolytic process. However, mTORC1, not mTORC2, is required for proper
adipocyte lipolysis to maintain circulating plasma lipid levels. Additionally, we provide
evidence that loss of adipocyte mTOR signaling is not solely responsible for the
rapamycin induced hyperlipidemia.
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CHAPTER 1: General Introduction
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1.1 Rapamycin
1.1.1 Discovery of Rapamycin
Rapamycin, an antifungal antibiotic, was discovered in 1975 (Vezina et al., 1975).
Cultures of a bacteria strain, Streptomyces hygroscopicus, were isolated from an Easter
Island (Rapa Nui) soil sample. The active antifungal principle was isolated in a crystalline
form and named rapamycin [Etymol.: Rapa- (Rapa Nui=Easter Island), -mycin.
Rapamycin is a white, crystalline solid with a melting point range of 183-185oC, and is
poorly soluble in water but readily soluble in ethanol, methanol, dimethylsulfoxide and
other organic solvents. Although the first chemical structure was proposed in 1980
(Findlay et al., 1980), the structure was not confirmed until total organic synthesis almost
ten years later (Hayward et al., 1993; Nicolaou et al., 1993; Romo et al., 1993).
Structural characterization showed rapamycin to be a mixture of two conformational
isomers because of the cis-trans rotation in the macrolidic lactone ring. This molecule
was discovered to have two structural domains, an effector domain and a binding
domain that facilitates the binding of rapamycin to FKBP12 (Figure 1.1) (Bierer et al.,
1990; Dumont et al., 1990a; Dumont et al., 1990b).
Rapamycin, a strong inhibitor of yeast growth, is mainly active against all strain of the
yeast, Candida albicans. Early studies demonstrated that rapamycin at a concentration
of 1.0 μg/ml did not inhibit the growth of this yeast during the first hour after addition to
media, however, a lower concentration of 5.0 ng/ml completely prevented growth after
addition to media. It prevents systemic and vaginal candidosis in mice with no acute
toxic side effects (Baker et al., 1978). Several other yeasts and dermatophytes,
filamentous fungi, are also sensitive to inhibition but to a lesser degree. No antibacterial
2

activity was demonstrated (Baker et al., 1978; Vezina et al., 1975). Initial
characterization of rapamycin was show to inhibit synthesis of nucleic acids, proteins
and lipids, as well as promoting degrading of macro molecules (Singh et al., 1979).
Two years after the discovery of rapamycin, immunosuppressive and anti-tumor
properties were discovered (Douros et al., 1981; Eng et al., 1984; Martel et al., 1977).
Although initially discovered as an antifungal metabolite, studies later revealed inhibitory
effects against production of humoral IgE. Studies also revealed preventive effects of
rapamycin in animal models of experimental autoimmune encephalitis and adjuvant
arthritis, two human autoimmune diseases (Martel et al., 1977). These studies
demonstrated the first recognized effects of rapamycin’s immunosuppressive activity.
Later studies showed prolongation of survival and prevention of the progression of
systemic lupus erythematosus in a MLR/lpr mouse model and exposed rapamycin’s
inhibitory effects against arthritis in rats (Kahan et al., 1991).
In 1990, studies were able to identify the molecular target of rapamycin. Rapamycin
binds to intracellular receptors called FK506 binding proteins (FKBPs). More specifically,
it forms a gain-of-function complex with the peptidyl-prolyl-isomerase (PPI) FKBP12.
Due to the conformation of rapamycin, it is believed to be energetically favorable for
FKBP12 binding (Van Duyne et al., 1991). FKBP12, an important FK506 binding protein,
is 12 kDa protein present in the cytosol that interacts with the immunosuppressant
FK506, to inhibit cell growth and proliferation (Dumont et al., 1990a; Dumont et al.,
1990b; Schreiber, S. L., 1991). Results from these studies showed that rapamycin and
FK506 compete for interaction with FKBP12.
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1.1.2 Identification of TOR
Identification of the targets of the FKBP12-rapamycin complex helped gain insight into
the molecular mechanisms of rapamycin’s actions. Several genetic studies in yeasts
identified two homologues of a protein named TOR, named target of Rapamycin
(Heitman et al., 1991; Kunz et al., 1993). TOR has emerged as a critical regulator of the
protein synthesis and cell growth in C. elegans, Drosophila, yeast, plants, and mammals.
Unlike yeast, which contain two TOR genes, higher eukaryotes have only a single TOR
gene (Crespo et al., 2005; Lee, S. et al., 2005).
Eukaryote TORs are large 280 kDa proteins and share 40%–60% sequence identity.
They belong to a group of kinases known as the phosphatidylinositol kinase-related
kinase (PIKK) family. PIKKs contain a carboxy-terminal serine/threonine protein kinase
domain which is similar to the catalytic domain of phosphatidylinositol 3-kinases (PI3Ks).
The FKBP12-rapamycin binding domain (FRB) is located at the amino-terminal region.
Single amino acid substitutions in FRB of TOR1 and TOR2 prevents the binding and
inhibition by the FKBP12-rapamycin complex. The amino-terminal portion of TOR
contains tandem HEAT repeats for protein-protein interactions (Wullschleger et al.,
2006).
Two separate genes TOR1 and TOR2 were mutated and loss of the functions of these
two proteins mimicked the effects of rapamycin treatment (Heitman et al., 1991; Stan et
al., 1994; Zheng et al., 1995). Purification of yeast TOR1 and TOR2 identified two
functionally and structurally different complexes. TORC1, a rapamycin sensitive
complex, and TORC2, a rapamycin insensitive complex (Loewith et al., 2002; Reinke et
al., 2004). Yeast TOR complex 1 also contained Kog1, Tco89, and lethal with SEC13
4

protein 8 (Lst8) with TOR1 or TOR2 (Adami et al., 2007; Loewith et al., 2002; Reinke et
al., 2004). Yeast TOR complex 2 also contained Avo1-3, Bit61, and Lst8 with TOR2
(Loewith et al., 2002; Wullschleger et al., 2005).
A few years after cloning of the yeast TOR gene, a mammalian cell ortholog was
discovered after screening proteins that interacted with the FKBP12-rapamycin complex.
Each group named the protein differently, rapamycin and FKP12 target 1 (RAFT1),
FKBP12-rapamycin associated protein (FRAP) or rapamycin target 1 (RAPT1) (Brown,
E. J. et al., 1994; Chiu et al., 1994; Sabatini et al., 1994). It wasn’t until 1995, when the
gene was cloned that it was named mammalian target of Rapamycin (mTOR), based on
the sequence homology with the yeast TOR proteins (Sabers et al., 1995). Although
mammals have only one MTOR gene, it forms two distinct complexes, mTORC1 and
mTORC2 (Saxton et al., 2017; Wullschleger et al., 2006).
The first component of mTORC1 identified was regulatory-associated protein of mTOR
(Raptor) (Hara et al., 2002; Kim, D. H. et al., 2002). This protein is responsible for
recruitment of substrates to mTORC1 by binding to the TOR signaling motif and for
subcellular localization of mTORC1 (Nojima et al., 2003; Sancak et al., 2008; Schalm et
al., 2003). Identification of Raptor-independent companion of mTOR (rictor) and
mammalian stress-activated protein kinase-interacting protein (mSin1), lead to the
existence of mTORC2 (Frias et al., 2006; Jacinto et al., 2006; Jacinto et al., 2004;
Sarbassov et al., 2004; Yang, Q. et al., 2006). Both complexes contain mammalian
LST8 (mLST8), a positive regulator of the complexes function, DEP domain-containing
mTOR-interacting protein (DEPTOR), an inhibitor of the complexes, and proline-rich

5

AKT substrate of 40 kDa (PRAS40), a mediator of growth factors and AKT signaling
(Saxton & Sabatini, 2017; Wullschleger et al., 2006; Wullschleger et al., 2005).

6

Figure 1-1. Rapamycin binding and inhibition of TOR.
(A). Chemical structure and domains of rapamycin. Rapamycin (sirolimus) has a binding
domain for FKBP12 and an effector Domain for TOR binding. common chemical moiety
that binds to the FKBP12 protein. (B) Rapamycin first binds to FKBP12, then the
protein–drug complex binds to the FKBP–rapamycin binding (FRB) domain on TOR to
inhibit TOR proteins, Other conserved domains in TOR proteins include tandem HEAT
repeats, a FAT domain, and a phosphoinositide 3-kinase–related kinase domain
(kinase). Reproduced with permission from Manning BD, (2017), Copyright
Massachusetts Medical Society (Manning, 2017).
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1.1.3 Clinical Uses
Rapamycin is clinically known as sirolimus. The earliest and most common clinical use
of rapamycin is as an immunosuppressant to prevent kidney and cardiac rejection after
transplantation. Rapamycin was first approved by the US Food and Drug Administration
(FDA) in September 1999 and the European Commission in March 2000 for use in
kidney trans- plantation. Rapamycin, and three analogs (CCI-779, RAD001 and
AP23573) have been tested for treatment of human cancer.
Rapamycin represses activation of T cells upon association with an antigen presenting
cell thereby strongly inhibiting proliferation of T cells. In this process, recognition of the
antigen by the T-cell receptor activates the AKT pathway, leading to mTORC1
stimulation and subsequent initiation of cell growth and proliferation (Chi, 2012).
Rapamycin also alters dendritic cell maturation, migration, antigen presentation and
apoptosis, thereby regulates antigen presenting cells (Thomson et al., 2009). This
initially made Rapamycin a promising drug especially since it had a better adverse effect
than commonly used immunosuppressing drugs. These drugs. such as Cyclosporine A
and FK506, caused nephrotoxicity, which is not observed with rapamycin treatment.
However, more recent data in patients treated primarily with rapamycin revealed
proteinuria and an increased risk of early transplant rejection compared to calcineurin
inhibitors, a steroid-sparing immunosuppressant used for over three decades in solid
organ transplantation (Langone et al., 2012). Currently, in transplant patients that have
developed secondary malignancies due to immune suppression, rapamycin is the first
choice in treatment. In this context, rapamycin has displayed excellent effects as a result
of its antiproliferative effects. In addition, rapamycin has been increasingly used in the
8

treatment of other disorders with immune system hyper activation. Clinical trials are have
been carried out to explore the effect of rapamycin treatment in systemic lupus
erythematosus, pemphigus, and uveitis.
Due to the poor water solubility of rapamycin, the development of two water-soluble
rapamycin analogs (rapalogs), temsirolimus (2007) and everolimus (2009) gained FDA
approval. In 2011, Everolimus was approved for use in progressive neuroendocrine
tumors of pancreatic origin (PNET) and has been tested in clinical trials for use against
advanced gastric cancer and advanced hepatocellular carcinoma. Clinical trials for
temsirolimus have been done to assess the use in treating advanced neuroendocrine
carcinoma (NEC), endometrial cancer and relapsed mantle cell lymphoma (MCL).
Ridaforolimus, another rapalog, has been clinically tested for its use in patients with
advanced bone and soft tissue carcinoma (Wander et al., 2011). However, since
mTORC1 regulates certain negative feedback loops, rapalogs have has limited
therapeutic for use in the treatment of major types of solid tumors.
1.1.4 Anti-Aging
The use of rapamycin as a lifespan extension agent has been extensively studied. The
relationship between TOR and longevity was first shown in non-vertebrates. In yeast,
deletion of SCH9, S6K homologue, or knockdown of TOR or daf-15, homologue of
Raptor, then main mTORC1 protein member, in worms extended lifespan (Fabrizio et
al., 2001; Jia et al., 2004; Vellai et al., 2003). In 2013, inhibition of mTOR was
discovered to promote lifespan extension in nematodes and fruit flies (Lamming et al.,
2013). Extension of lifespan has also been proven in mammals. 18-24 months of
Rapamycin treatment in both male and female mice starting from either 9th or 20th
9

months of age extended both median and maximal lifespan (Harrison et al., 2009). A
study in 2012 was designed to test age-dependent effects of mice treated with
rapamycin from 9th to 21st month of age. These results demonstrated that age-related
pathologies occur slower in mice treated with rapamycin (Wilkinson et al., 2012). In
2013, a study to test the age-independent effects of rapamycin was conducted.
C57BL/6j mice were treated with rapamycin for 12 months starting at 4, 13 or 20 months
of age. This study reported that extended lifespan in rapamycin treated mice but there
was no effect on age related pathologies (Neff, F. et al., 2013). Based off these studies,
it has since been concluded that rapamycin has an age-independent effect due to the
improved effects in older and well as young mice.
1.1.5 Metabolic Side Effects
Recent advances in immunosuppressant drugs for solid organ transplant patients has
decreased rates of rejection and increased life span of the transplant recipients.
However, long term side effects including dyslipidemia and accelerated atherosclerosis
still remain a problem. The most common clinical use of rapamycin is as an
immunosuppressant to prevent kidney and cardiac rejection after transplantation.
Sirolimus and other mTOR inhibitors such as everolimus and temsirolimus is commonly
associated with adverse effects (Neff, G. W. et al., 2003). For cardiac transplants,
hyperlipidemia occurs in 60% within one month and increases to 90% of patients within
10 years (Rudas et al., 1990; Taylor et al., 2008). For renal and liver transplants,
hyperlipidemia occurs in over 50% of patients (Charco et al., 1999; Gisbert et al., 1997;
Ramezani et al., 2007; Tse et al., 2004). In patients treated with rapamycin, serum
triglycerides increase by 20% in over 50% of patients (Brattstrom et al., 1998; Firpi et al.,
10

2004; MacDonald et al., 2001; Trotter et al., 2001). In kidney transplant patients that
develop rapamycin-induced hypertriglyceridemia, using an in vivo kinetic study, it has
been shown that hypertriglyceridemia was mostly due to decreased VLDL catabolism
(Hoogeveen et al., 2001). In that study, rapamycin treatment was associated with a 70%
decrease in VLDL-ApoB100 catabolism and a decrease post-heparin LPL activity
(Hoogeveen et al., 2001). Interestingly, it was shown that insulin upregulates LPL activity
in a PI3K dependent manner and that this regulation was decreased by 60% in the
presence of rapamycin (Kraemer et al., 1998). In addition, rapamycin treatment is
associated with a 92% increase in ApoCIII, which is a potent inhibitor of LPL. In addition,
rapamycin treatment induced a 42% increase in free fatty acids, suggesting augmented
release of free fatty acids from the adipose tissue. This study suggest that this may be
due to a reduction of the inhibition of the hormone-sensitive lipase by insulin(Morrisett et
al., 2002).
The mechanisms by which sirolimus causes dyslipidemia remains unclear, but some
studies have suggested that both an increase in VLDL synthesis (increased in
apolipoprotein B) and a decrease in triglyceride hydrolysis (increased apolipoprotein
CIII) (Hoogeveen et al., 2001; Morrisett et al., 2002; Tur et al., 2000). While other claims
that the hyperlipidemia associated with rapamycin is not likely due to increased lipid
hepatic synthesis but rather due to delayed peripheral clearance (Brown, N. F. et al.,
2007). It has been postulated that this increase in free fatty acids may increase hepatic
VLDL production, but such increase in VLDL production has not been clearly shown in
human kinetic studies (Hoogeveen et al., 2001).
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Mice studies have also observed adverse metabolic effects of rapamycin. KK/HIJ mice
on a high fat diet showed aggravated glucose intolerance after treatment with rapamycin
for six weeks (Chang et al., 2009b). Two weeks of rapamycin treatment in rats caused
hyperlipidemia. This study suggested the hyperlipidemia was due to increased hepatic
gluconeogenesis and impaired deposition of lipids in adipose tissue (Houde et al., 2010).
A later study established that mTORC1 inhibition increased lifespan while mTORC2
inhibition resulted in insulin resistance (Lamming et al., 2012). Another study compared
the effects of rapamycin on metabolism in mice after 2, 6 and 20 weeks of rapamycin
treatment (Fang et al., 2013). The 2 week rapamycin treated group showed larger livers
and smaller pancreas as compared to groups treated for longer. However, prolonged
rapamycin treatment led to a decrease in adipose tissue. Rapamycin treatment affected
the lipid profile in mice in proportional to the length of treatment. In addition, insulin was
increased after 2 weeks of rapamycin treatment, causing the mice to become glucose
intolerant and insulin resistant. Improved insulin sensitivity was reported in rapamycin
treated mice treated for the longer durations of 6 weeks and 20 weeks (Fang et al.,
2013).
1.2 Mammalian Target of Rapamycin (mTOR)
1.2.1 Structure of mTOR
Mammalian target of Rapamycin (mTOR) is a Ser/Thr protein kinase that belongs to the
phosphatidylinositol 3-kinase-related kinases (PIKKs) superfamily which regulate cellular
growth and differentiation (Ma, X. M. et al., 2009). mTOR is a 289 kDa protein comprised
of 2549 amino acids. The structure of mTOR has six major domains. At the N-terminus
are around 32 tandem HEAT (Huntingtin, elongation factor 3 (EF3), a subunit of PP2A,
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and TOR) repeats, with each repeat comprised of ~ 40 amino acids. These repeats form
a super helical structure and aids in protein-protein interaction (Andrade et al., 2001;
Baretic et al., 2016). A ~600 residue FAT (named after FRAP, ATM, and TRRAP)
domain, which consists of a-a helical repeats that wraps partial around the kinase
domain. A ~100 residue FRB (FKBP12 Rapamycin binding) domain that forms a four
helix bundle. The FRB domain resides between the FAT and catalytic domains and acts
as a gatekeeper for Rapmycin-FKBP12 binding (Choi et al., 1996; Yang, H. et al., 2013).
A ~300 residue catalytic domain which forms a canonical two-lobed structure with key
insertions in both the amino-terminal and the carboxy-terminal lobes. A ~40 residue LBE
domain, which forms the binding site for mLST8. Lastly, a ~35 residue FAT-C domain at
the carboxy terminus and is required for kinase activity (Takahashi et al., 2000). The six
mammalian PIKKs contain three homologous domains; the FAT domain, catalytic
domain, and the FAT-C domain (Andrade et al., 1995; Aylett et al., 2016; Bosotti et al.,
2000; Yang, H. et al., 2013).
Although mTOR is expressed extensively in human tissues, levels are significantly
higher is testis and skeletal muscle (Brown, E. J. et al., 1994; Chiu et al., 1994). Human
mTOR shares 44% identity with the yeast TOR1 and 46% identity with the yeast TOR2.
The 600 amino acids of their C-terminal region share the greatest sequence similarity of
all three proteins, suggesting that mammalian mTOR and yeast TORs may have similar
enzymatic activities. However, the other domains, which includes the N-terminal region,
share little to no sequence similarity.
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1.2.2 mTOR Complexes: mTORC1 and mTORC2
Unlike yeast, higher eukaryotes, have only one MTOR gene. However, it forms two
distinct TOR complexes: mTORC1 and mTORC2. Efforts from many laboratories have
revealed the molecular architecture comprising each complex (Wullschleger et al.,
2006). mTOR integrates external nutrient cues to cellular growth and proliferation
(Laplante et al., 2012). The two mTOR complexes have differential sensitivities to
rapamycin – with mTORC1 more sensitive than mTORC2 (Sabatini, 2006). A notable
initial contribution was the identification of regulatory-associated protein of mTOR
(Raptor) as an mTORC1 component (Hara et al., 2002; Kim, D. H. et al., 2002). The
existence of mTORC2 was demonstrated by the identification of Raptor-independent
companion of mTOR (Rictor) and mammalian stress-activated protein kinase-interacting
protein (mSin1) (Frias et al., 2006; Jacinto et al., 2006; Jacinto et al., 2004; Sarbassov et
al., 2004; Yang, Q. et al., 2006). Mammalian LST8 (mLST8) is a common core
component of both mTORC1 and mTORC2 and positively contributes to their functions.
DEP domain-containing mTOR-interacting protein (DEPTOR) also associates with
mTORC1 and mTORC2, but acts to inhibit the two complexes. Another mTORCassociated protein is proline-rich AKT substrate of 40 kDa (PRAS40). PRAS40 may also
mediate growth factor and AKT signals to mTORC1 and mTORC2.
As in yeast, the FKBP12–rapamycin complex directly binds to and inhibits mTORC1
kinase activity and function, but does not directly inhibit mTORC2. Studies of mTORC1
structure have provided insights into the inhibitory mechanism of action of rapamycin
(Aylett et al., 2016; Stuttfeld et al., 2018; Yang, H. et al., 2013). Rapamycin, however,
seems to inhibit only part of mTORC1 functions (Choo et al., 2008; Kang et al., 2013).
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Rapamycin leads to a strong decrease in phosphorylation of ribosomal subunit S6kinase
(S6K1) but only a slight decrease in phosphorylation of eukaryotic initiation factor 4E
(eIF4E) binding protein 1 (4EBP-1) (Kang et al., 2013; Yoon, S. O. et al., 2013). In most
cell types, mTORC2 is insensitive to short term treatment with rapamycin (Oshiro et al.,
2004; Sarbassov et al., 2004). However, long-term rapamycin treatment can abrogate
mTORC2 signaling, probably due to the destabilization of the mTORC2 complex, in
many cell lines and tissues in vivo, including hepatocytes, adipose tissue, skeletal
muscle, heart, pancreases, liver, lung and spleen (Lamming et al., 2012; Sarbassov et
al., 2006; Schreiber, K. H. et al., 2015).
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Figure 1-2. Upstream and downstream mTORC1 and mTORC 2.
(A). Upstream sensors and downstream function of mTOR complex 1. (B) Upstream
sensors and downstream function of mTOR complex 2. Reproduced with permission
from (Papadopoli et al., 2019).
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1.2.3 Upstream mTORC1
In the presence of pro-growth endocrine signals, sufficient energy and chemical building
blocks for macromolecular synthesis, mTORC1 activity shifts toward increased
anabolism. These inputs are mainly dependent on diet. Therefore, mTORC1 is activated
upon refeeding leading to the promotion of growth and energy storage in tissues. The
opposite occurs during fasting to conserve limited nutrients and resources.
In the early 1990s, studies of rapamycin revealed that mTORC1 is a downstream
mediator of several growth factor and mitogen dependent signaling pathways, which
inhibit Tuberous Sclerosis Complex (TSC), a key negative regulator of mTORC1
signaling. Numerous growth factor pathways converge on TSC, including the
insulin/insulin-like growth factor-1 (IGF-1) pathway, in which AKT phosphorylates and
inhibits TSC2 (Inoki et al., 2002; Manning et al., 2002).TSC functions as a GTPase
activating protein for the Rheb, a small GTPase (Inoki et al., 2003a; Tee et al., 2003).
Rheb directly binds and activates mTORC1 (Long et al., 2005; Sancak et al., 2007).
Receptor tyrosine kinase-dependent Ras signaling also activates mTORC1 via the MAP
Kinase ERK which also phosphorylates and inhibit TSC2 (Ma, L. et al., 2005; Roux et
al., 2004). Other growth factor pathways upstream of TSC include WNT and TNFa, an
inflammatory cytokine, which both activate mTORC1 through inhibition of TSC1 (Inoki et
al., 2006; Lee, D. F. et al., 2007). mTORC1 also responds to intracellular and
environmental stresses that are unsuitable for cellular growth. For example, during
glucose deprivation, the stress responsive metabolic regulator AMPK is activated and
inhibits mTORC1. Inhibition in this pathway occur both directly, through the
phosphorylation of Raptor and indirectly, through phosphorylation of TSC2 (Gwinn et al.,
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2008; Inoki et al., 2003b; Shaw et al., 2004). However, in cells lacking AMPK, glucose
deprivation inhibits mTORC1 through inhibition of the Rag GTPases (Efeyan et al., 2013;
Kalender et al., 2010). Hypoxia also inhibits mTORC1 in part through AMPK activation,
and through the induction of REDD1 (Regulated in DNA damage and development 1).
REDD1 also activates TSC (Brugarolas et al., 2004). The DNA damage-response
pathway inhibits mTORC1 through the induction of p53 target genes which increases
TSC activity (Feng et al., 2007).
Feeding leads to an increase in serum amino acid levels from the digestion of dietary
proteins. mTORC1 activation is linked to changes in amino acid concentrations from the
diet. Briefly, amino acid stimulation converts Rag GTPases to their active form, which
they then bind to Raptor and recruit mTORC1 to close proximity of Rheb. In this
pathway, mTORC1 signaling is only activate when both the Rags and Rheb are
activated. mTORC1 senses both intra-lysosomal and cytosolic amino acids through
distinct mechanisms. Several additional mechanisms by which amino acids regulate
mTORC1 signaling have also been reported.
1.2.4 mTORC1 Downstream Signaling
As two well-characterized and critical downstream targets of mTORC1, ribosomal
subunit S6kinase (S6K1) and eukaryotic initiation factor 4E (eIF4E) binding protein 1
(4EBP-1) mediate translation regulation and protein synthesis in cells upon
phosphorylation by mTORC1 (Foster et al., 2010). mTORC1 also phosphorylates many
metabolic enzymes to regulate cell growth and post-transcriptional regulation of lipid
metabolism. In addition, mTORC1 stimulates cell growth by suppression of protein
catabolism, through autophagy.
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In absence of growth factors, unphosphorylated S6K1 and 4EBP-1 are associated with
eukaryotic initiation factor (eIF)-3 complex and eIF4E, respectively. In response to
growth factors, mTORC1 phosphorylates S6K and 4EBP-1. After phosphorylation by
mTORC1 on Thr389, which dissociates S6K1 from eIF3 from S6K1, S6K1 then
phosphorylates eukaryotic translation initiation factor 4B (eIF4B), a positive regulator of
the 5′ cap-binding eIF4F complex, this phosphorylation results in activation (Brunn et al.,
1997; Gingras et al., 1999; Holz et al., 2005). S6K1 also phosphorylates programmed
cell death protein 4 (PDCD4). This phosphorylation results in the degradation of
PDCD4, an inhibitor of eIF4A (Dorrello et al., 2006). S6K1, through casein kinase 1
(CK1), leads to phosphorylation and activation of SRPK2. SRPK2 is a key RNA-binding
regulator in mRNA processing This downstream effect modifies splicing of pre-mRNAs
that encoded lipogenic enzymes (Ma, J. et al., 2006). 4EBP-1 is phosphorylated by
mTORC1 at multiple sites (Brunn et al., 1997; Gingras et al., 1999). After
phosphorylation, 4EBP-1, unrelated to S6K1 signaling, is released from eIF4E (Hay et
al., 2004). This inhibits translation by binding and sequestering of eIF4E to 4EBP-1,
preventing formation of the eIF4F complex. Short term mTOR inhibition, as with
rapamycin treatment, relatively suppressed general mRNA translation. However, the
greatest effects where on mRNAs that contain pyrimidine-rich 50 TOP motifs. This
comprises many genes involved in protein synthesis (Hsieh et al., 2012; Thoreen et al.,
2012).
mTORC1 also phosphorylates many metabolic enzymes to regulate cell growth and
post-transcriptional regulation of lipid metabolism (Lee, G. et al., 2017). Through an
S6K1-dependent mechanism, mTORC1 promotes de novo lipid synthesis by activating
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the sterol regulatory element-binding protein (SREBP) transcription factors, which
control expression of fatty acid and cholesterol synthesis genes (Duvel et al., 2010;
Porstmann et al., 2008). mTORC1 directly phosphorylates Lipin 1, which inhibits SREBP
in the absence of mTORC1 signaling (Peterson, T. R. et al., 2011). In addition, mTORC1
activation of SREBP increases flux through the oxidative pentose phosphate pathway
(PPP). This pathway uses carbons from glucose to produce intermediate metabolites
needed for proliferation and growth. mTORC1 facilitates growth by altering glucose
metabolism. This is done by inducing a shift from oxidative phosphorylation to glycolysis.
mTORC1 also increases translation of HIF1a, a transcription factor that increases the
expression of glycolytic enzymes, such as phosphofructo kinase (PFK) (Duvel et al.,
2010).
In DNA replication and ribosome biogenesis for growing and proliferating cells, mTORC1
promotes the synthesis of nucleotides. mTORC1 increases ATF4-dependent expression
of MTHFD2, a key protein that provides one-carbon units for purine synthesis (BenSahra et al., 2016). Through phosphorylation of S6K1, mTORC1 activates carbamoylphosphate synthetase (CAD), which is a critical protein in de novo pyrimidine synthesis
(Ben-Sahra et al., 2013; Robitaille et al., 2013). mTORC1 promotes cell growth by
suppressing protein catabolism, mainly by autophagy. ULK1 is involved in the early step
of autophagy. This kinase forms a complex with ATG13, FIP2000, and ATG101, driving
the formation of autophagosome. In absence of growth factors, mTORC1
phosphorylates ULK1, which prevents activation by AMPK (Kim, J. et al., 2011).
mTORC1 also phosphorylates and inhibits the nuclear translocation of the transcription
factor EB (TFEB). TFEB induces gene expression for lysosomal biogenesis and
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autophagy processes (Martina et al., 2012; Roczniak-Ferguson et al., 2012; Settembre
et al., 2012). A second major way mTORC1 regulates protein turnover is through the
ubiquitin-proteasome system (UPS). This pathway selectively targets proteins for
degradation by the 20S proteasome following modification with ubiquitin. Inhibition of
mTORC1 increases UPS through an increase in either protein ubiquitination, or through
inhibition of ERK5, which increases the amount of proteasomal chaperones (Rousseau
et al., 2016; Zhao et al., 2015). On the contrary, hyper activation of mTORC1 signaling
can also lead to an increase in proteasome activity. This downstream signaling is
mediated through NRF1, which increases the expression of proteasome subunits
(Zhang, Y. et al., 2014).
1.2.5 Upstream mTORC2
In contrast to mTORC1, mTORC2 primarily functions as an effector of insulin/PI3K
signaling. The mTORC2 subunit mSin1 contains a phosphoinositide-binding PH domain
critical for insulin-dependent regulation of mTORC2 activity. In the absence of insulin,
the PH domain of mSin1 inhibits mTORC2 catalytic activity (Liu, P. et al., 2015). mSin1
can also be phosphorylated by AKT, indicative of a positive-feedback loop where partial
activation of AKT induces the activation of mTORC2, which mTORC2 then can
phosphorylate leading to fully activated AKT (Yang, G. et al., 2015). In addition, another
study showed that PI3K promotes localization of mTORC2 to ribosomes which activates
mTORC2 kinase activity, although the mechanism remains unclear (Zinzalla et al.,
2011). mTORC1 also regulates mTORC2 signaling due to the negative feedback loop
between mTORC1 and insulin/PI3K signaling. mTORC1 downstream target, Grb10, is a
negative regulator of insulin/IGF-1 receptor signaling residing upstream of mTORC2,
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(Hsu et al., 2011; Yu et al., 2011). In addition, S6K1 suppresses mTORC2 activity
through the phosphorylation-dependent degradation of insulin receptor substrate 1
(IRS1) (Harrington et al., 2004; Shah et al., 2004).
1.2.6 mTORC2 Downstream Signaling
While mTORC1 regulates cell growth and metabolism, mTORC2 controls proliferation
and survival. mTORC2 phosphorylate several members of the AGC (PKA/PKG/PKC)
family of protein kinase to control proliferation and survival. The first mTORC2 substrate
to be identified was PKCa, a regulator of the actin cytoskeleton (Jacinto et al., 2004;
Sarbassov et al., 2004). mTORC2 also phosphorylates several other members of the
PKC family, including PKCd, PKCz, and PKCg (Gan et al., 2012; Li, X. et al., 2014;
Thomanetz et al., 2013). The PKC family regulate various aspects of cytoskeletal
remodeling and cell migration. Serum and glucocorticoid inducible kinase (SGK1), a
AGC-kinase that regulates ion trans- port as well as cell survival is another other wellknown mTORC2 targets (Garcia-Martinez et al., 2008).
A critical role of mTORC2, however, is the phosphorylation and activation of AKT, a key
effector of insulin/ PI3K signaling (Sarbassov et al., 2005). AKT is phosphorylated at two
sites for complete activation. Phosphorylation at T308 by phosphoinositide-dependent
kinase (PDK)-1 at the plasma membrane. and phosphorylation at S473 by mTORC2.
Complete activation of AKT regulates processes like cellular growth, and apoptosis
through the phosphorylation and subsequent inhibition of several key substrates. These
substrates include the FoxO1/3a transcription factors, the metabolic regulator GSK3b,
and the mTORC1 inhibitor TSC2. In glucose metabolism, phosphorylated AKT promotes
glucose transporter type (GLUT)-4 translocation to the plasma membrane, allowing
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glucose uptake in response to insulin stimulation (Kohn et al., 1996; Manning et al.,
2007). In addition, activated AKT regulates de novo fatty acid synthesis through
activation of ATP-Citrate Lyase (ACL) (Berwick et al., 2002).
1.3 Lipid Metabolism
1.3.1 Lipoproteins and Lipid Transport
Exogenous Lipoprotein Pathway
The exogenous lipoprotein pathway starts with the incorporation of dietary lipids into
chylomicrons (CM) in the intestine. In the fed state, the absorbed fatty acids and
monoacylglycerols are utilized to synthesize triglycerides. The key enzymes required for
triglyceride synthesis are monoacylglycerol acyltransferase (MGAT) and diacylglycerol
transferase (DGAT). MGAT catalyzes the addition of a fatty acid to monoacylglycerol
while DGAT catalyzes the addition of a fatty acid to diacylglycerol resulting in triglyceride
formation. The triglycerides and cholesterol esters are packaged into chylomicrons in the
endoplasmic reticulum. The formation of chylomicrons in the endoplasmic reticulum
requires the synthesis of Apo B-48 by the intestinal cell. Microsomal triglyceride transfer
protein (MTP) is required for the movement of lipid from the endoplasmic reticulum to the
Apo B-48. The absence of MTP results in the inability to form chylomicrons
(Abetalipoproteinemia) (Dallinga-Thie et al., 2010). Chylomicrons are secreted to the
systemic circulation and not delivered directly to the liver via the portal circulation. This
facilitates the delivery of the nutrients contained in the chylomicrons to adipose tissue. In
the circulation the triglycerides carried in chylomicrons are metabolized in adipose tissue
by lipoprotein lipase (LPL) and chylomicron remnants are formed. The chylomicron
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remnants are then taken up by the liver. Chylomicrons (CM) are large triglyceride rich
particles made by the intestine, which are involved in the transport of dietary triglycerides
and cholesterol to peripheral tissues and liver. Apo B-48 is the core structural protein
and each chylomicron particle contains one Apo B-48 molecule. The size of
chylomicrons varies depending on the amount of fat ingested. A high fat meal leads to
the formation of large chylomicron particles due to the increased amount of triglyceride
being transported. The exogenous lipoprotein pathway results in the efficient transfer of
dietary fatty acids to adipose tissue for energy utilization and storage. The cholesterol is
delivered to the liver where it can be utilized for the formation of VLDL, bile acids, or
secreted back to the intestine via secretion into the bile. In normal individuals this
pathway can handle large amounts of fat (100 grams or more per day) without resulting
in marked increases in plasma triglyceride levels. In fact, in a normal individual, a meal
containing 75 grams of fat results in only a very modest increase in postprandial
triglyceride levels.
The Endogenous Lipoprotein Pathway
The endogenous lipoprotein pathway begins in the liver with the formation of very low
density lipoproteins (VLDL). VLDL are triglyceride rich. They contain apolipoprotein B100, C-I, C-II, C-III, and E. Apo B-100 is the core structural protein and each VLDL
particle contains one Apo B-100 molecule. Similar to chylomicrons the size of the VLDL
particles can vary depending on the quantity of triglyceride carried in the particle. When
triglyceride production in the liver is increased, the secreted VLDL particles are large. In
the fasted state, liver triglycerides and cholesterol esters are transferred in the
endoplasmic reticulum to newly synthesized Apo B-100. Similar to the intestine this
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transfer is mediated by MTP. The availability of triglycerides is the primary determinant
of the rate of VLDL ApoB-100 synthesis. If the supply of triglyceride is limited the newly
synthesized Apo B is rapidly degraded. Thus, in contrast to many proteins the rate of
synthesis of the Apo B-100 is not the major determinant of the rate of secretion. Rather
the amount of lipid available determines whether Apo B-100 is degraded or secreted.
MTP is required for the early addition of lipid to Apo B-100 particles but additional lipid is
added via pathways that do not require MTP. Loss of function mutations in either Apo B100 or MTP result in the failure to produce VLDL and marked decreases in plasma
triglyceride and cholesterol levels (Familial hypobetalipoproteinemia or
abetalipoproteinemia) (Tiwari et al., 2012). VLDL particles are transported to peripheral
tissues where the triglycerides are hydrolyzed by LPL and fatty acids are released. This
process is very similar to that for chylomicrons and there is competition between the
metabolism of chylomicrons and VLDL. High levels of chylomicrons can inhibit the
clearance of VLDL. The removal of triglycerides from VLDL results in the formation of
VLDL remnants (Intermediate density lipoproteins (IDL)). In a pathway analogous to the
removal of chylomicron remnants these IDL particles can be removed from the
circulation by the liver via binding of Apo E to LDL and LRP receptors. However, while
the vast majority of chylomicron remnants are rapidly cleared from the circulation by the
liver, only a fraction of IDL particles are cleared (approximately 50% but varies). The
remaining triglycerides in the IDL particles are hydrolyzed by hepatic lipase leading to a
further decrease in triglyceride content and the exchangeable apolipoproteins are
transferred from the IDL particles to other lipoproteins leading to the formation of LDL,
which are taken up by via the LDL receptor in numerous tissues including the liver,
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which is the predominant site of uptake. These LDL particles predominantly contain
cholesterol esters and Apo B-100. Thus, LDL is a product of VLDL metabolism.
Lipoprotein Lipase
In muscle and adipose tissue lipoprotein lipase (LPL) is expressed at high levels. LPL
belongs to a family of lipases, which includes hepatic lipase, and endothelial lipase, and
hydrolyzes triglycerides in in chylomicrons and very low-density lipoproteins (VLDL).
The hydrolyzed triglycerides yields two free fatty acids and on monoacylglycerols (MG)
(Mead et al., 2002; Rinninger et al., 1998). LPL is composed of two distinct regions. The
active site of LPL is in the N-terminal domain (Mead et al., 2002; Rinninger et al., 1998;
Wang, C. S. et al., 1992). The C-terminal domain appears to confer LPL’s substrate
specificity; it has a higher affinity for large triacylglyceride-rich lipoproteins than
cholesterol-rich lipoproteins (Lookene et al., 2000). Lipids interacts with the active site
(Mead et al., 2002). The gene that encodes lipoprotein lipase, which is expressed in the
heart, muscle, and adipose tissue. LPL is controlled transcriptionally and post
transcriptionally (Wang, H. et al., 2009). LPL isozymes are differentially regulated
depending on the tissue. In adipocytes, insulin activates LPL and its secretion to the
capillary endothelium. In muscle, insulin decreases expression of LPL (Kiens et al.,
1989). In muscle and heart, LPL is activated by glucagon and adrenaline (Braun et al.,
1992; Mead et al., 2002).
LPL is synthesized in skeletal and cardiac muscle in the fasted state and in adipocytes in
fed state. After translation, the newly synthesized protein is glycosylated in
the endoplasmic reticulum. Homodimerization is occurs prior to secretion from cells (Ong
et al., 1989; Vannier et al., 1989). LPL is then secreted as a homodimer and
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translocated across endothelial cells to the capillary lumen by the
protein glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1
(Beigneux et al., 2007; Davies et al., 2010; Mead et al., 2002). A conformational change
occurs in order for LPL to form homodimers and become catalytically active (Braun &
Severson, 1992; Semb et al., 1989; Wong et al., 1994). Lipase maturation factor 1
(LMF1) plays a key role in the stabilization and movement of LPL from muscle cells and
adipocytes to the capillary endothelial cell surface. Glycosylphosphatidylinisitol anchored
high density lipoprotein binding protein 1 (GPIHBP1) anchors LPL to the capillary
endothelium.
The concentration of LPL on the surface of endothelial cells is regulated by managing
the flux of secreted LPL and by the activity of LPL present on the endothelium. A key
protein involved in controlling the activity of LPL is ANGPTL4, a local inhibitor of LPL.
Expression of ANGPTL4 accounts for the inhibition of LPL activity in white adipose
tissue during fasting (Dijk et al., 2014; Zhang, R., 2016). Feeding induces the
ANGPTL8–ANGPTL3 pathway to inhibit LPL in cardiac and skeletal muscles, directing
circulating triglycerides for uptake by white adipose tissue. The reverse is true during
fasting, directing triglycerides to muscles (Zhang, R., 2016).
Activation of LPL by Apo C-II, carried on the chylomicrons, leads to the hydrolysis of the
triglycerides that are carried in the chylomicrons resulting in the formation of free fatty
acids, which can be taken up by the adjacent adipocytes for either energy production or
storage. Fatty acid transport proteins (FATPs) and CD36 facilitate the uptake of fatty
acids into adipocytes and muscle cells. Some of the free fatty acids released from
chylomicrons bind to albumin and can be transported to other tissues.
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The glycerol backbone of the lipid is then able to enter the active site and is hydrolyzed.
it is believed that release of product into circulation is the rate-limiting step in the reaction
(Wang, C. S. et al., 1992).
Loss of function mutations in LPL, Apo C-II, GPIHPB1, lipase maturation factor 1, and
Apo A-V can result in marked hypertriglyceridemia (chylomicronemia). In addition, there
are proteins that inhibit LPL activity. Apo C-III inhibits LPL activity and loss of function
mutations in this gene are associated with increases in LPL activity and decreases in
plasma triglyceride levels. Similarly, angiopoietin like protein 3 and 4, which target LPL
for inactivation, regulate LPL activity. Loss of function mutations in these proteins also
are associated with decreases in plasma triglyceride levels. In mice, overexpression of
LPL has been shown to cause insulin resistance, and to promote obesity (Delezie et al.,
2012; Ferreira et al., 2001; Kim, J. K. et al., 2001).
1.3.2 Lipolysis
Lipolysis is the process by which triglycerides (TG) are hydrolyzed to free fatty acids
(FFA) and glycerol. In adipocytes, this is achieved by sequential action of adipose TG
lipase (ATGL), hormone-sensitive lipase (HSL), and monoacylglycerols (MG) lipase. The
activity in the lipolytic pathway is tightly regulated by hormonal and nutritional factors.
Under conditions of negative energy balance such as fasting and exercise, stimulation of
lipolysis results in a profound increase in FFA release from adipose tissue (AT). This
response is crucial in order to provide the organism with a sufficient supply of substrate
for oxidative metabolism. However, failure to efficiently suppress lipolysis when FFA
demands are low can have serious metabolic consequences and is believed to be a key
mechanism in the development of type 2 diabetes in obesity.
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The primary role of adipose tissue is to release stored fatty acids during times of
increased energy demand, such as exercise or fasting. Lipolysis involves the sequential
hydrolysis of triacylglycerols (TG) by specific enzymes and results in the liberation of a
fatty acid at each step with the generation of diacylglycerols (DG), monoacylglycerols
(MG) and glycerol. This process is controlled by three major lipases; adipose triglyceride
lipase (ATGL), hormone-sensitive lipase (HSL) and monoacylglycerols lipase (MAGL)
(Tsiloulis et al., 2015). Lipolysis is tightly regulated by a number of pro-lipolytic and antilipolytic (e.g. insulin) hormones. Upon ß-adrenergic activation, a cascade of signaling
events results in maximal ATGL and HSL activity via phosphorylation events, protein–
protein interactions and accumulation on the surface of lipid droplets, facilitating direct
interaction between the lipases and TG (Arner et al., 2014; Tsoli et al., 2016). Lipolysis is
suppressed by insulin via mechanisms that antagonize the ß-adrenergic pathway
(Morigny et al., 2016).
Three independent laboratories identified ATGL as a major triglyceride lipase in 2004
(Jenkins et al., 2004; Villena et al., 2004; Zimmermann et al., 2004). ATGL is the ratelimiting enzyme in the lipolytic cascade, exhibiting high substrate specificity for TG, and
very weak activity against DG (Eichmann et al., 2012; Zimmermann et al., 2004).
Pioneering studies in ATGL−/− mice demonstrated reduced basal and catecholaminestimulated lipolysis and increased adipocyte mass compared with control mice, clearly
demonstrating that ATGL is a crucial lipase in the lipolytic chain. Phosphorylation at
ATGL Ser406 (Ser404 in humans) increases lipolysis in adipocytes and there is no
known functional role for the other phosphorylation sites (Haemmerle et al., 2006).
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Phosphorylation of ATGL at Thr372 is required for ATGL to localize to the lipid droplet
for efficient lipolysis, although the activating kinase is unknown (Xie et al., 2014).
PLIN1 is a lipid droplet associated protein which acts as a ‘scaffold’ by facilitating access
of lipases to the lipid droplet and mediating protein–protein interactions in adipocytes. Its
most prominent role is to reduce lipolysis under ‘basal’ or ‘spontaneous’ conditions.
PLIN1 binds CGI-58 with high affinity and suppresses the interaction of CGI-58 and
ATGL, thereby suppressing lipolysis and facilitating TG accumulation (Granneman et al.,
2009). PLIN1 phosphorylation by PKA is necessary for maximal lipolysis (Brasaemle et
al., 2009). Key phosphorylation sites maximize the activation of ATGL-dependent
lipolysis, and the fragmentation and dispersion of lipid droplets to increase the surface
area for lipase binding in mice, and are conserved in humans, suggesting similar
regulation (Marcinkiewicz et al., 2006; McDonough et al., 2013). Germline ablation of
Plin1 result in animals with increased basal lipolysis and decreased stimulated lipolysis
(Tansey et al., 2001).
1.3.3 Lipogenesis
De novo sterol and fatty acid synthesis are regulated by signaling pathways, mainly the
insulin signaling pathway. Both hepatocytes and adipocytes synthesize significant
amounts of lipid de novo. This fatty acid biosynthesis pathway involves cytosolic acetylCoA, derived from glucose or amino acid catabolism, to form the hydrophobic carbon
backbone of lipids through acetyl-CoA carboxylase. This process comprises many steps
requiring many specific enzymes. The most important protein is the SREBPs,
transcription factors that stimulate the expression of genes encoding lipogenic enzymes
(Horton, 2002). The three SREBP isoforms are encoded by two genes. Under conditions
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of abundant nutrients, full-length SREBP is retained in the endoplasmic reticulum,
preventing cleavage into the isoforms (Jeon et al., 2012). Depletion of intracellular
nutrients results in transport to the Golgi, in cleavage release the active SREBP, which
then enters the nucleus and induces transcription. SREBP1a and 1c are primarily
implicated in the control of genes involved in fatty acid synthesis (Shimano et al., 1997).
SREBP2 plays a role in the transcription of steroidogenic and cholesterol genes (Horton
et al., 1998; Horton et al., 2003; Linden et al., 2018; Rong et al., 2017). Although the
different SREBP isoforms activate transcription of different sets of genes, there is
overlap between the targets of the different isoforms. The tissue specificity of these
preferences, which has not been fully established. Lipin-1 is a phosphatidic acid
phosphatase required for glycerolipid biosynthesis. This protein also serves as a
transcriptional coactivator that regulates the expression of lipogenic genes (Csaki et al.,
2010).
1.3.4 Adipogenesis and Adipose Tissue
White adipose tissue is known as an organ that regulates systemic lipid homeostasis by
storing and releasing free fatty acids (Rutkowski et al., 2015; Tran, T. T. et al., 2010).
Adipose tissue is essential for normal health. Multiple metabolic defects that occur in
patients with lipodystrophies, are characterized by decreased adipose tissue (HuangDoran et al., 2010; Qiang et al., 2016). In contrast, the excessive accumulation of fat in
the form of triglycerides is associated with metabolic dysfunctions. These dysfunctions
can cause insulin resistance and type 2 diabetes, cardiovascular disease, and some
cancers (Bjorndal et al., 2011; Despres, 2006; Tran, T. T. & Kahn, 2010).
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Adipose tissue is mainly categorized as white (WAT) or brown (BAT) based on several
criteria. This includes intracellular lipid droplet morphology, mitochondrial number and
metabolic functions (fat storage vs fat catabolism). There is a third type of adipocyte, the
‘beige’ adipocyte, which stems from white adipocytes upon cold exposure or other
stimuli. ‘Beige’ adipose shares structural and functional features of both WAT and BAT
(Kajimura et al., 2010). WAT is most abundant adipose depot, comprising 5-60% of body
mass (Lee, M. J. et al., 2013). Adipose tissue is mostly located in subcutaneous
locations (i.e. under the skin) (Park et al., 2014). Subcutaneous adipose tissue
comprises up to ∼80% of the whole-body adipose mass. The omental, retroperitoneal,
mesenteric and perigonadal depots make up the majority of the visceral adipose tissue,
which is located within the intra-abdominal regions and contributes to ∼5– 20% of body
mass (Lee, M. J. et al., 2013).
Adipogenesis, a complex developmental process, involves commitment of multipotent
stem cells to adipose lineage and the accumulating lipids to form mature adipocytes
(Cawthorn et al., 2012). Several transcription factors regulate the differentiation of
preadipocytes into mature adipocytes. These transcription factors include the
CCAAT/enhancer-binding proteins (C/EBPs) and peroxisome proliferator-activated
receptor-γ (PPARγ), which is a nuclear receptor needed for the whole adipogenic
program. When preadipocytes are stimulated to differentiate, expression of C/EBPδ and
C/EBPβ is activated. This prompts the induction of C/EBPα and the expression of
PPARγ, which directly promotes the expression of genes involved in fatty acid
metabolism, triglyceride metabolism, and lipid storage.
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1.4 mTORC 1 and 2 in Lipid Metabolism
The transition between fasting and feeding is accompanied by profound alterations in
circulating levels of nutrients and growth factors. These changes modulate whether
anabolic or catabolic processes are turned on in tissues. Postprandial metabolism, the
period during or after refeeding, is very dynamic and allows tissues to efficiently use and
store the ingested nutrients to support anabolism. Cells require an ample amount of
lipids to provide support for energy metabolism and membrane biogenesis. Lipogenesis
is a cellular process by which acetyl-CoA is converted to fatty acids. This important
anabolic process occurs in several tissues following refeeding and is dependent on
circulating insulin levels (Kersten, 2001). mTOR activation, in addition to promoting
anabolism, also blocks several catabolic processes. In the fasting state, levels of
nutrients and growth factors are limited. Adipose tissue lipolysis, the breakdown of
intracellular triglycerides, provides fuel for utilization by other tissues in need of nutrients
(Zechner et al., 2012). This process is inhibited by both mTOR complexes when excess
nutrients are readily available. Since mTOR signaling pathways responds to nutrient and
growth factor levels, the roles of both complexes in regulating lipogenesis and lipolysis
has been extensively studied over the past few years.
1.4.1 mTOR Complexes in Lipogenesis
mTORC1
mTORC1 plays a central role in promoting lipid biogenesis by regulating the expression
of many lipogenic genes, most importantly sterol regulatory element-binding proteins
(SREBPs), transcription factors involved in lipid synthesis (Laplante et al., 2013).
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mTORC1 positively regulates the activation of SREBPs at multiple levels, which includes
processing, trafficking, and transcription (Bakan et al., 2012). In 2008, it was discovered
that rapamycin prevents the nuclear accumulation of mSREBP1, normally mediated
through AKT, and the subsequent induction of lipogenic genes (Porstmann et al., 2008).
Previous studies have also reported that rapamycin reduces the expression of several
lipogenic genes (Mauvoisin et al., 2007; Peng, T. et al., 2002). Deletion of Raptor, but
not Rictor, prevents SREBP1 processing and decreases the expression of lipogenic
genes (Porstmann et al., 2008). This was also observed in vivo. Mice treated with
rapamycin had reduced hepatic SREBP1 processing and decreased lipogenic gene
expression (Yecies et al., 2011). S6K1 has also been proven to regulate SREBPs
processing downstream of mTORC1 signaling (Duvel et al., 2010; Li, S. et al., 2010; Liu,
X. et al., 2012; Owen et al., 2012; Wang, B. T. et al., 2011). Genetic deletion of the TSC
complex in vitro, which leads to increased mTORC1 signaling, stimulated nuclear
accumulation of mSREBP1 and de novo lipogenesis (Duvel et al., 2010). In liver-specific
Tsc1 null mice, constitutive mTORC1 activation worsened the feedback inhibition of
insulin signaling, which also worsened AKT activity. Decreased AKT signaling correlated
with increased expression of Insig2a, an inhibitor of SREBP1 (Yecies et al., 2011). An
increase in insulin also induces expression of Srebf1 in the liver (Foretz et al., 1999;
Horton et al., 1998; Shimomura et al., 1999). This process is inhibited with both
pharmacological and genetic inhibition of mTORC1 (Duvel et al., 2010; Li, S. et al.,
2010; Owen et al., 2012; Porstmann et al., 2008; Titchenell et al., 2016; Wan et al.,
2011; Yecies et al., 2011). mTORC1 also regulates SREBPs through phosphorylation of
Lipin-1, which induces the nuclear accumulation of SREBPs (Peterson, T. R. et al.,
2011). These studies demonstrate the importance of mTORC1 in regulating lipogenesis.
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mTORC2
mTORC2 also plays a critical role in modulating lipid synthesis. Deletion of Rictor in the
liver decreases SREBP activity, the expression of lipogenic genes, and lipid
accumulation in the liver (Hagiwara et al., 2012; Yuan et al., 2012). Deletion of Rictor in
brown adipose tissue lead to a decrease in lipogenesis (Hung et al., 2014). Proposed
mechanism of action differs between. In the liver-specific Rictor KO mice,
overexpression of a constitutively activated AKT isoform rescued the defects in
lipogenesis (Hagiwara et al., 2012). Loss of mTORC2-mediated AKT phosphorylation on
Serine 473 partially reduces AKT function, which impair SREBP1 activation AKT has
been shown to control lipogenesis through its action on SREBP1, through Insig2a, direct
phosphorylation SREBP1, and by blocking glycogen synthase kinase 3-mediated
degradation of mSREBP1 (Bengoechea-Alonso et al., 2009; Sundqvist et al., 2005;
Yabe et al., 2003; Yecies et al., 2011; Yellaturu et al., 2009).
1.4.2 mTOR Complexes in Lipolysis
Rapamycin treatment in vivo and in vitro has been shown to stimulate adipocyte
triglyceride hydrolysis and free fatty acid release (Aggarwal et al., 2006; Chakrabarti et
al., 2010; Houde et al., 2010; Lopes et al., 2014; Morrisett et al., 2003; Pereira et al.,
2013; Soliman et al., 2010). Several studies suggest that mTORC1 can affect lipolysis,
however, activation of lipolysis observed with rapamycin can also be due to the indirect
inhibition of the mTORC2 (Chakrabarti et al., 2010; Chakrabarti et al., 2013). Additional
studies are needed to better understand the mechanisms of action and the contribution
of each mTOR complex to the regulation of lipolysis.
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mTORC1
Various experimental conditions link mTORC1 and adipose tissue. Humans and animal
treated with rapamycin had increased plasma free fatty acids (Aggarwal et al., 2006;
Houde et al., 2010; Morrisett et al., 2003; Soliman et al., 2010). Similarly, isolated
adipocytes treated with rapamycin increased ex vivo basal and stimulated lipolysis
(Chakrabarti et al., 2010; Lopes et al., 2014; Pereira et al., 2013). In differentiated 3T3L1 cells, rapamycin treatment or Raptor deletion had the same effect (Chakrabarti et al.,
2010; Soliman et al., 2010). Overexpression of Rheb, which leads to activation of
mTORC1, inhibited lipolysis in 3T3-L1 cells (Chakrabarti et al., 2010). In isolated
adipocytes, loss of S6K1 induced lipolysis and loss of 4E-BP1 reduced this effect (Le
Bacquer et al., 2007; Um et al., 2004). Results from these genetic studies suggest a
direct role for mTORC1 signaling in the control of triglyceride break down and fatty acid
release from adipocytes. However, one study using mice with adipose-specific deletion
of Raptor, did not observe any effect on lipolysis (Polak et al., 2008). Although the
reason for this inconsistency is unknown, this study used mice expressing cre
recombinase under the promoter of the fatty acid binding protein 4 (Fabp4) gene which
encodes adipocyte protein 2 (aP2), which has been shown to not be adipocyte specific
(Graves et al., 1992; Lee, K. Y. et al., 2013; Mullican et al., 2013; Shan et al., 2013; Urs
et al., 2006).
It has been suggested that mTORC1 affects the lipolysis through expression of adipose
triglyceride lipase (ATGL), the rate limiting enzyme that initiates the first step of lipolysis,
converting triglycerides to diacylglycerols (Zechner et al., 2012). Overexpression of
mTORC1 signaling has been shown to reduce expression of Atgl (Chakrabarti et al.,
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2010). In vitro and in vivo studies demonstrated that inhibition of mTORC1 by rapamycin
increases Atgl expression. It has been proposed that mTORC1, upon activation by
insulin or growth factors, regulates Atgl expression by increasing levels of transcription
factor early growth response-1 (EGR1) (Chakrabarti et al., 2013). Although the
mechanism of how mTORC1 increases EGR1 is unknown, EGR1 has been shown to
inhibit expression of Atgl by binding directly to the promoter. Upon refeeding, decreases
in plasma free fatty acids occur within one hour, suggesting that the regulation of
triglyceride hydrolysis occur through posttranslational modifications, not through
changes in lipase expression (Hernandez et al., 2010; Laplante et al., 2003; Zechner et
al., 2012). Therefore, mTORC1 transcriptional regulation of Egr1 and Atgl most likely
does not play a role in the inhibition of lipolysis upon refeeding.
Independent of changes in ATGL, inhibition of mTORC1 by rapamycin has been shown
to increase lipolysis, by stimulating protein kinase A (PKA)-mediated phosphorylation of
hormone-sensitive lipase on Ser563 (Soliman et al., 2010). Phosphorylation of this site is
necessary for complete hydrolysis of triglycerides (Shen et al., 1998). This study
reported that the inhibition of mTORC1 increased catecholamine-stimulated lipolysis,
which was independent of changes in the levels of intracellular cAMP and
phosphorylation of PKA.
mTORC2
mTORC2 has also been shown to negatively regulate adipose tissue lipolysis. Adiposespecific KO of Rictor decreases the ability of insulin to suppress lipolysis of adipocytes
(Kumar et al., 2010). These adipose-specific Rictor KO mice displayed elevated plasma
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glycerol and free fatty acid levels, ectopic fat deposition, and developed insulin
resistance. This higher lipolytic rate was linked to reduced phosphorylation of AKT,
increased activity of PKA, and increased higher phosphorylation of HSL on Ser563.
These results suggest that mTORC2 mediates triglyceride breakdown in fat cells through
the antilipolytic functions of AKT. However, not all studies on adipose-specific Rictor KO
mice yielded the same results. One study did not observe any changes in plasma free
fatty acids with loss of mTORC2 (Cybulski et al., 2009). The reason for this discrepancy
is not clear but could be due to differences in experimental procedures.
1.4.3 mTOR Complexes in Adipogenesis
mTORC1
Many studies support a role for mTORC1 in the regulation of adipogenesis. These
studies, using rapamycin, reported that rapamycin abrogates adipocyte differentiation in
various cell lines in vitro (Bell et al., 2000; Cho et al., 2004; El-Chaar et al., 2004;
Gagnon et al., 2001; Kim, J. E. et al., 2004; Polak et al., 2008; Yeh et al., 1995; Zhang,
H. H. et al., 2009). Because prolonged treatment with rapamycin can sometimes inhibit
mTORC2, specific contribution of mTORC1 in adipogenesis requires genetic inhibition of
mTORC1 (Lamming et al., 2012; Sarbassov et al., 2006). Polak et al. knocked down
Raptor, the essential mTORC1 component, in 3T3-L1 preadipocytes (Polak et al., 2008).
In this model, loss of mTORC1 signaling drastically impaired adipogenesis. A similar
result was observed when mouse embryonic fibroblasts (MEFs) with deletion of Raptor
were differentiated in vitro (Polak et al., 2008). MEFs with constitutively activate
mTORC1 by deletion of Tsc2, yielded the opposite result, with increased adipogenesis
(Zhang, H. H. et al., 2009). The regulation of mTORC1 on adipogenesis has also been
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proven in animal models. Several groups have shown that rapamycin treatment in
rodents decreases adipose tissue (Chang et al., 2009a; Chang et al., 2009b; Houde et
al., 2010). Using the Cre-Lox approach on mice with the Raptor gene floxed, in vivo
effects of mTORC1 in adipose tissue regulation can be studied. Initial in vivo studies
utilized the aP2 promoter, however this targets not only the adipose but other tissues
(Lee, K. Y. et al., 2013; Martens et al., 2010). Nevertheless, these mice had impaired
lipid accumulation in adipose tissue and were protected from diet induced obesity (Polak
et al., 2008). It was originally reported that rapamycin blocks the clonal expansion of
preadipocytes into mature adipocytes, thus impairing adipogenesis (Yeh et al., 1995).
Later, other groups studied the effect of rapamycin following induction of adipocyte
differentiation. Rapamycin treatment still impaired adipogenesis indication that mTORC1
regulates adipose terminal differentiation, most likely through a mechanism independent
of the effects on proliferation (Bell et al., 2000; Cho et al., 2004; Gagnon et al., 2001).
These findings support another groups results in which rapamycin inhibits the
expression of C/EBPs and PPARg, co-regulators of transcriptional activity in adipose
differentiation. In addition, the two main downstream mTORC1 targets, S6K1 and 4EBPs have also been shown to regulate adipocyte formation. Mice null for S6K1 were not
able to increase adipocyte cell number, and had decreased expression of early
adipogenic transcription factors, C/EBPs (Carnevalli et al., 2010). In addition, KD of
S6K1 or inhibition with PF4708671 prevented preadipocytes differentiation in vitro
(Yoon, M. S. et al., 2013). However, over expression of S6K1 was unable to rescue
rapamycin’s suppression of adipogenesis (Kim, J. E. & Chen, 2004). MEFs with loss of
4E-BP1/2 (similar state to constitutive active mTORC1), had increased expression of
C/EBPa and PPARg in vitro (Le Bacquer et al., 2007).
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mTORC2
In response to insulin, AKT stimulates glucose uptake and activates adipogenesis by
promoting the activation of PPARg (Kohn et al., 1996; Magun et al., 1996; Menghini et
al., 2005; Nakae et al., 2003; Peng, X. D. et al., 2003; Rosen et al., 2006; Shearin et al.,
2016). Therefore, it was first assumed that mTORC2 would play a key role in regulating
adipogenesis. However, adipose-specific Rictor, the essential component of mTORC2,
KO mice did not display any defect in adipose proliferation or accumulation (Cybulski et
al., 2009; Kumar et al., 2008). Thus, it was concluded that mTORC2 is non-essential for
adipogenesis in vivo, more specifically, terminal differentiation and adipocyte
maintenance. In order to study the role of mTORC2 in the initial phases of adipocyte
development, one group used Rictor floxed mice with myogenic factor 5 (Myf5)-Cre
recombinase, which will delete Rictor from white adipocyte progenitors (Hung et al.,
2014). These mice accrued less adipose mass. Reports from two other studies, utilizing
deletion of Rictor in MEFs or adipocyte precursors also impaired early adipogenesis
(Hung et al., 2014; Yao et al., 2013).
1.5 Goal of this work
Aging is associated with a gradual decline in physiological functions of tissues (Sabatini,
2017). The process of aging in certain tissues can lead to a variety of disorders, this
includes neurodegeneration, obesity, diabetes, and cardiovascular (Vezina et al., 1975).
mTOR, which plays central role in age-related processes, represents an appealing target
to ameliorate age-related pathologies. Rapamycin, an inhibitor of mTOR signaling, is the
main pharmacological agent that can prolong lifespan in several model organisms
(Baker et al., 1978).
40

Despite the studies that support the role of rapamycin or rapalogs to expand life span,
the function as an immunosuppressant might be of concern. A decline in immune
function leads to infection-related morbidity and mortality in the elderly (Murphy, 2010;
Saxton & Sabatini, 2017). Another limitation of rapamycin is the inhibition of mTORC2
after chronic exposure in mice (Lamming et al., 2012; Sarbassov et al., 2006). In
addition to rapamycin, active-site mTOR inhibitors also inhibit mTORC2 (Bhat et al.,
2015). Inhibition of mTORC2 reduces life span and is associated with adverse changes
in metabolism, such as insulin resistance, which negatively impacts life span (Lamming,
2014; Soukas et al., 2009). Therefore, much effect is being invested in developing
specific inhibitors that suppress all mTORC1 signaling, including phosphorylation of 4EBP1, but do not effect on mTORC2 signaling,
There is mounting evidence suggesting that both mTOR complexes are involved in lipid
mobilization and transport. Metabolic dysfunction, such as obesity, induces chronically
elevated mTORC1 signaling in liver and adipose, further contributing to the development
of hypertriglyceridemia, resulting from the hyperglycemia and hyperinsulinemia
associated with obesity (Haas, J. T. et al., 2012; Haas, M. E. et al., 2013; Khamzina et
al., 2005; Um et al., 2004). In type 2 diabetes and insulin resistance, mTORC1 signaling
remains active most likely due to persistent hyperinsulinemia, leading to increased de
novo lipogenesis. Concurrently, insulin resistance in adipose also stimulates a steady
increase in lipolysis, causing an increase in NEFA in the circulation. NEFA are mainly
delivered to the liver but in excess, these lipids can accumulate in organs such as the
skeletal muscle, pancreas, and heart, commonly referred to as ectopic fat deposition
(Haas, M. E. et al., 2013; Hocking et al., 2013; Snel et al., 2012). The central role of
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mTORC1 in regulating lipid homeostasis and its persistent activation in obesity and type
2 diabetes suggests mTORC1 inhibitors would offer therapeutic benefits in metabolic
diseases. However, patients treated with mTORC1 inhibitors experience increased
insulin resistance, hypertriglyceridemia, hypercholesterolemia, and elevated plasma FFA
(Kasiske et al., 2008). Accordingly, plasma levels of both ApoB100 and ApoCIII were
increased in rapamycin treated patients, indicating elevated circulating VLDL (Aggarwal
et al., 2006; Morrisett et al., 2002). However, these studies only examined the effects of
lipids in the fasted state. Lipid homeostasis requires a balance in lipid storage and
synthesis in the fed state as well. Despite that mTOR inhibition clearly extends life span,
the negative side effects associated with direct inhibition of mTOR complexes provide
support for the identification of potential bioactive and therapeutic compounds capable of
mitigating the adverse metabolic side effects. However, there are still outstanding
questions regarding the negative metabolic effects and much work is still needed to fill
the gaps in knowledge related to the function of mTOR in the context of lipid
homeostasis. This work fills in some of those gaps in knowledge
In the experiments described below, we asked whether mTORC1 and mTORC2
signaling in adipocyte influences whole body lipid homeostasis, and if inhibition of these
complexes induces hyperlipidemia. We also asked whether adipose tissue mediates the
adverse lipid effects of rapamycin treatment. In addition, answers to these questions will
fill in the gaps of knowledge that remain regarding the roles of mTOR in adipose tissue.
We show that loss of either mTORC1 or mTORC2 results in hyperlipidemia, suggesting
that mTOR is required in vivo for adipocyte maintenance of lipid homeostasis. We show
that enhanced lipolysis upon refeeding increases plasma triglyceride levels in the
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context of rapamycin treatment and that both complexes are involved in regulating this
lipolytic process. However, mTORC1, not mTORC2, is required for proper adipocyte
lipolysis to maintain circulating plasma lipid levels. Additionally, we provide evidence that
loss of adipocyte mTOR signaling is not solely responsible for the rapamycin induced
hyperlipidemia.
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CHAPTER 2: mTORC1 restrains adipocyte lipolysis to prevent
systemic hyperlipidemia (Paolella et al., 2020)
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2.1 Abstract
Pharmacological agents targeting the mTOR complexes are used clinically as
immunosuppressants and anticancer agents, and can extend lifespan in model
organisms. An undesirable side effect of these drugs is hyperlipidemia. Despite multiple
roles that have been described for mTOR complex 1 (mTORC1) in lipid metabolism, the
etiology of hyperlipidemia remains incompletely understood. The objective of this study
was to determine the influence of adipocyte mTORC1 signaling in systemic lipid
homeostasis in vivo. We characterized systemic lipid metabolism in mice lacking the
mTORC1 subunit raptor (RaptoraKO), the key lipolytic enzyme ATGL (ATGLaKO), or both
(ATGL-RaptoraKO) in adipocytes. Mice lacking mTORC1 activity in adipocytes failed to
completely suppress lipolysis in the fed state and displayed prominent
hypertriglyceridemia and hypercholesterolemia. Blocking lipolysis in adipose tissue
restored normal levels of triglycerides and cholesterol in the fed state, as well as the
ability to clear triglycerides in an oral fat tolerance test. Unsuppressed adipose lipolysis
in the fed state interferes with triglyceride clearance and contributes to hyperlipidemia.
Adipose tissue mTORC1 activity is necessary for appropriate suppression of lipolysis
and for the maintenance of systemic lipid homeostasis.
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2.2 Introduction
Therapeutic inhibition of mechanistic Target Of Rapamycin (mTOR) is important for
immunosuppression and for the treatment of certain cancers (Benjamin et al., 2011).
Recently, interest in this pathway has been heightened by the demonstration that the
prototypical mTOR inhibitor, rapamycin, extends lifespan in model organisms from yeast
to rodents (Harrison et al., 2009; Medvedik et al., 2007; Miller et al., 2011). However,
these studies have also served to highlight our incomplete understanding of the
mechanisms by which mTOR signaling influences physiology in different cell types, and
of the etiology of the undesirable side effects that can accompany mTOR inhibition,
which include an increased risk of new-onset diabetes and dyslipidemia, a major risk
factor for cardiovascular diseases (Morrisett et al., 2003; Parekh et al., 2012). mTOR is a
serine/threonine protein kinase that nucleates two structurally and functionally distinct
complexes, mTORC1 (characterized by the presence of RAPTOR) and mTORC2
(characterized by the presence of RICTOR) (Benjamin et al., 2011). mTORC1 is the
canonical target of rapamycin and is acutely inhibited by the drug, whereas mTORC2 is
only disrupted after chronic rapamycin treatment in specific cell types and in vivo due to
sequestration of the catalytic mTOR subunit (Lamming et al., 2012; Sarbassov et al.,
2006; Schreiber, K. H. et al., 2015). mTORC1 is regulated by anabolic signals and
amino acid availability to suppress autophagy and promote protein, lipid, and nucleic
acid synthesis as well as nutrient transport (Kennedy et al., 2016). mTORC2 plays key
roles in metabolism, cell survival and proliferation through multiple mechanisms
including regulation of the insulin/IGF1 signaling cascade via phosphorylation of AKT at
S473 (Kennedy & Lamming, 2016). Targeted disruption of mTORC1 or mTORC2 has
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revealed that each complex has distinct and tissue-specific effects on signaling and
metabolism (Kennedy & Lamming, 2016). Genetic or pharmacological targeting of the
mTOR complexes has been shown to influence pathways that are important for whole
body lipid homeostasis in vivo. These include changes in the expression of hepatic
genes involved in lipogenesis and triglyceride (TG) secretion, suppression of lipoprotein
lipase (LPL) activity, and over-activation of lipolysis via increased ATGL expression or
PKA activity in adipocytes (Chakrabarti et al., 2013; Hagiwara et al., 2012; Houde et al.,
2010; Kraemer et al., 1998; Soliman et al., 2010; Tory et al., 2008; Yecies et al., 2011;
Yuan et al., 2012). However, the relative importance of these pathways and how they
interact remain unclear. Indeed, an increase in circulating TG after mTOR inhibition is
somewhat paradoxical, given that mTORC1 promotes lipogenesis, and genetic ablation
of either mTOR complex in the liver results in unaltered or decreased plasma lipids,
rather than an increase (Peterson, T. R. et al., 2011; Quinn et al., 2017; Yuan et al.,
2012). In cultured adipocytes, mTORC1 inhibition decreases de novo lipogenesis and
increases lipolysis, the latter proposed to be via either upregulation of ATGL expression
or increased PKA-dependent phosphorylation of HSL (Chakrabarti et al., 2010;
Chakrabarti et al., 2013; Soliman et al., 2010). After rapamycin treatment, the effects on
lipolysis have been less clear, with increased circulating non-esterified fatty acids
(NEFA) reported in some studies and decreased NEFA in others (Blanchard et al., 2012;
Fang et al., 2018; Fang et al., 2013; Houde et al., 2010; Lopes et al., 2014). Decreased
expression and activity of lipoprotein lipase have been more consistently observed after
rapamycin treatment in vivo (Blanchard et al., 2012; Kraemer et al., 1998; Morrisett et
al., 2003; Pereira et al., 2013; Tory et al., 2008). Genetic ablation of adipocyte mTORC1
with AP2-Cre resulted in lean mice that were protected from hypercholesterolemia
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(Polak et al., 2008). However, this Cre can have off-target and mosaic effects (Lee, K. Y.
et al., 2013). We and others have since generated a mouse model lacking Raptor
specifically in adipocytes using adiponectin-Cre and reported increased (Tran, C. M. et
al., 2016) or unchanged NEFA (Lee, P. L. et al., 2016). Lee et al. further described
progressive lipodystrophy with increased de novo lipogenesis in adipocytes, and upward
trends but no significant changes in cholesterol and TG (Lee, P. L. et al., 2016). In sum,
the available data do not identify a clear or consistent role for adipocyte mTORC1
signaling in systemic lipid homeostasis, and prior studies have been somewhat
confounded by concurrent lipodystrophy. Here we studied mice with adipose-specific
Raptor ablation (RaptoraKO) prior to the onset of lipodystrophy. We show that these
animals display profound hypertriglyceridemia specifically in the fed state. Although
lipoprotein lipase expression is decreased, the effect size is small, and this change alone
does not explain the lipidomic profile in adipose tissue, which favors accumulation of diand monoacylglycerols. While, RaptoraKO mice have lower NEFA than controls during
fasting, they have higher NEFA in the fed state, suggesting a failure to appropriately
suppress lipolysis and potentially explaining why in vivo studies on rapamycin have
reached opposite conclusions with respect to its effects on circulating NEFA. Strikingly,
genetic ablation of ATGL to limit adipocyte lipolysis largely restored triglyceride
homeostasis without correcting the deficiency in lipoprotein lipase expression. These
results suggest that unrestrained lipolysis is the primary defect in hyperlipidemia induced
by adipocyte mTORC1 inhibition in vivo.
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2.3 Results
2.3.1 Adipocyte-specific loss of mTORC1 activity elevates plasma lipids prior to
lipodystrophy
To investigate the role of adipose mTORC1 on plasma lipid metabolism, we generated
mice with adipose-specific deletion of Raptor (RaptoraKO), which encodes an essential
subunit of mTORC1. Deletion of Raptor in inguinal white adipose tissue (IWAT),
epididymal white adipose tissue (EWAT) and brown adipose tissue (BAT), along with the
expected reduction in phosphorylation of mTORC1 targets, ribosomal protein S6 and
eukaryotic translation initiation factor 4E binding protein 1 (4EBP1) was confirmed by
western blot (Figure 2.1A,B, Supplementary Fig, 2.1A-C). We also observed an increase
in phosphorylation of AKT as expected due to the loss of negative feedback on the
insulin signaling cascade (Huang et al., 2009). Deletion of Raptor did not change body
weight in male (Figure 2.1C) or female mice (Supplementary Figure 2.1D), despite the
onset of lipodystrophy by about 3 months of age, as reported previously (Lee, P. L. et
al., 2016). We noted elevated expression of macrophage markers in EWAT
(Supplementary Figure 2.1F) and relative adipose mass decreased with age in both
genders, while liver mass increased (Figure 2.1D, Supplementary Figure 2.1E). In
contrast to the mild or protective lipid phenotypes observed in previous studies, we
noted consistent hypertriglyceridemia in RaptoraKO mice (Supplementary Figure 2.1G,H).
To avoid the confounding effects of decreased adipose tissue mass, we studied mice at
~10 weeks of age, a time point at which the sizes of adipose depots were similar
between genotypes (Figure 2.1E). At this age, we also saw no evidence of hepatic
steatosis (Supplementary Figure 2.1I). We found that random fed plasma cholesterol
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and triglycerides were increased in RaptoraKO compared to controls, and that a trend
toward increased non-esterified fatty acids (NEFA) was also apparent (Figure 2.1F). We
conclude that RaptoraKO mice develop hyperlipidemia prior to lipodystrophy.
2.3.2 Plasma lipid levels are sensitive to adipocyte mTORC1 status in the fed state
Hyperlipidemia has not been reported in previous studies of mice lacking adipocyte
mTORC1 signaling, and conflicting reports exist as to the effect of pharmacologic
mTORC1 inhibition on NEFA. To determine whether changes in feeding state might
explain these apparent contradictions, we subjected mice to an overnight fast and
subsequent four-hour period of refeeding. We found that the effect of adipocyte
mTORC1 ablation on circulating TG is entirely feeding state-dependent. In the fasted
state, plasma TG were similar between RaptoraKO mice and controls, whereas in the
refed state RaptoraKO mice displayed profound elevations in circulating TG (Figure 2.2A).
Moreover, RaptoraKO mice displayed significantly lower NEFA in the fasted state, when
lipolysis is normally activated, but significantly higher NEFA in the fed state, when
lipolysis would normally be repressed (Figure 2.2B). Compared to controls, RaptoraKO
mice gained a similar amount of weight during refeeding and maintained similar blood
glucose levels, suggesting that the altered lipid parameters were not due to changes in
food intake (Supplementary Figure 2.2). We hypothesized that higher NEFA in the fed
state might lead to an increase in re-esterification to TG in the liver and secretion as
VLDL particles, which could explain the elevation of plasma TG. However, the rate of
hepatic TG secretion (assessed by blocking lipase activity with nonionic surfactant P-407
and monitoring the rate of increase of plasma TG) was unchanged in RaptoraKO mice in
either the fasted or the fed state, despite higher levels of plasma TG before P-407
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injection in the refed condition (Figure 2.2C). Next, we administered an oral fat tolerance
test, which bypasses first-pass hepatic metabolism, to measure TG clearance.
Consistent with an extrahepatic cause for hypertriglyceridemia, RaptoraKO mice displayed
increased plasma TG compared to controls (Figure 2.2D). This finding indicates a defect
in the clearance of plasma TG in RaptoraKO mice.
2.3.3 Adipocyte-specific ablation of mTORC1 activity causes a modest deficiency in
lipoprotein lipase expression
To determine the cause of delayed clearance in the RaptoraKO mice we examined
lipoprotein lipase (LPL) gene expression and activity. LPL plays a central role in the
clearance of lipid from plasma by hydrolyzing TG to NEFAs and monoacylglycerols
(MG). LPL protein translocates from the cell of origin to the luminal surface of endothelial
cells, where it is bound by proteoglycans and can act on circulating lipoprotein particles.
LPL is active in adipose tissue after feeding, and can be released into the circulation by
administration of heparin. We found that Lpl gene expression is decreased in IWAT and
EWAT from RaptoraKO mice (Figure 2.3A). Consistent with a defect in adipocyte Lpl
expression in RaptoraKO mice, we observed a decrease in heparin-releasable LPL
activity in the fed state, but not during fasting (Figure 2.3B). Direct assay of LPL activity
extracted from tissue lysates revealed decreases in the IWAT and BAT of refed
RaptoraKO mice (Figure 2.3C). In contrast, we were not able to measure a defect in
EWAT, despite the reduction in Lpl mRNA level. Although the reason for this
discrepancy is not clear, we speculate that reduced shedding of LPL into the
bloodstream may help maintain tissue levels in the RaptoraKO mice. Overall, decreases in
LPL activity were significant, but generally mild in the RaptoraKO mice. Thus, we sought
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to test whether other factors might also contribute to the hyperlipidemia and
lipodystrophy in RaptoraKO animals.
2.3.4 Lipidomic profiling reveals accumulation of lipolytic intermediates in adiposespecific mTORC1 KO mice
To gain further insight into the alterations in adipocyte lipid metabolism that occur in the
absence of mTORC1 signaling, we assayed lipidomic profiles in adipose from RaptoraKO
mice and wild type littermates in the refed state at 10 weeks of age. Simple inhibition of
LPL would be expected to decrease the abundance of NEFA, monoacylglycerols (MG)
and diacylglycerols (DG) in adipose tissue, since fewer of these metabolites would be
released from circulating TG and available for re-esterification. In contrast, the lipidomic
profiles revealed an increase in the abundance of MG and DG species, and a decrease
in total TG content in RaptoraKO adipose (Figure 2.4 A-E). Relative abundances for each
lipid species in Raptorfl/fl vs. RaptoraKO mice are listed in Supplementary Table 2.1. The
increases in MG and DG suggest that either re-esterification is impaired or lipolysis is
activated. These possibilities can be distinguished because lipolysis results in the
release of free glycerol, whereas LPL-dependent hydrolysis of TG leaves the glycerol
moieties trapped as MG. We found that RaptoraKO mice in the refed state exhibited
elevated glycerol concentrations, pointing to increased lipolysis as a driver of elevated
NEFA in this model (Figure 2.4F).
2.3.5 Genetic inhibition of lipolysis ameliorates hyperlipidemia in adipose-specific
mTORC1 KO mice
To limit lipolysis in the context of Raptor deletion, we concurrently deleted adipocyte
triglyceride lipase (ATGL), which encodes the rate-limiting enzyme for hydrolysis of
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adipocyte TG during lipolysis (Figure 2.5A, B). ATGL protein levels in the liver were not
altered upon adipose specific ATGL deletion (Supplementary Figure 2.3A). Although
body weight was unchanged, IWAT, EWAT and BAT weights were increased in both
ATGLaKO and ATGL-RaptoraKO mice (Supplementary Figure 2.3B,C). ATGL loss restored
refed plasma NEFA to normal levels in RaptoraKO mice in vivo (Figure 5C) and blocked
the increase in basal lipolysis observed explants derived from RaptoraKO EWAT (Figure
2.5D). ATGL loss also prevented the induction of lipolysis by CL316,243 in both
genotypes. In addition to the expected effects on lipolysis, ATGL deletion prevented the
increase in refed plasma TG levels in RaptoraKO mice (Figure 2.5E). Plasma cholesterol
was also restored to normal levels (Supplementary Figure 2.3D). To exclude potential
consequences of chronic deletion in the genetic models, we tested the effects of acute
inhibition of mTORC1 and ATGL on ex vivo lipolysis. Inhibition of mTORC1 with
rapamycin increased basal lipolysis and the addition of the ATGL inhibitor atglistatin was
able to prevent the increase (Figure 2.5F). Notably, ATGL-RaptoraKO mice did not have
significantly altered Angptl4 mRNA as compared to controls, and had the same
reductions in Plin1 and Lpl mRNA that were observed in RaptoraKO (Supplementary
Figure 2.3E,F). This suggests the possibility that unrestrained lipolysis, rather than a
defect in LPL expression, is the primary cause of impaired lipid clearance in RaptoraKO
mice, consistent with the suggestion that LPL might be subject to feedback inhibition by
NEFA and MG (Amri et al., 1996; Bengtsson et al., 1980; Saxena et al., 1989). However,
mice lacking adipocyte ATGL have decreased hepatic TG stores, and lower plasma TG
levels during fasting. Therefore, it could also be speculated that this decrease in fasting
plasma TG might buffer the increase upon refeeding. To more directly test the ability of
ATGL-RaptoraKO mice to clear a fixed load of TG, we performed an oral fat tolerance
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test. Concurrent loss of ATGL restored the ability of RaptoraKO mice to clear exogenous
TGs, limiting the increase in plasma TG to that seen in floxed littermates (Figure 2.5G).
Although starting TG levels were lower with loss of ATGL, the rate of clearance and area
under the curve were comparable to those of wildtype mice (Figure 2.5H). Thus,
unrestrained lipolysis impairs clearance circulation of TG-rich lipoproteins in RaptoraKO
mice.
2.3.6 Stimulating lipolysis is sufficient to delay clearance of plasma TG in WT mice
Our results to this point demonstrated that lipolysis drives hyperlipidemia in the context
of RaptoraKO mice, which have multiple alterations in lipid-handling pathways. To
determine whether increased lipolysis per se is sufficient to impair the clearance of TG in
wild type mice, we performed an oral fat tolerance test with or without stimulation of
lipolysis with the b3-adrenergic agonist CL316,243. CL316,243 injection substantially
increased plasma NEFA, as expected (Figure 2.6A). In mice that received the
CL316,243 injections, clearance of the exogenous TG was also dramatically slowed,
resulting in hyperlipidemia (Figure 2.6B). In contrast, CL316,243 did not increase plasma
NEFA or plasma TG in mice lacking ATGL (Supplementary Figure 2.4). We next
measured hepatic TG secretion to test whether CL316,243 could be slowing the
apparent TG clearance rate by enhancing hepatic re-esterification of NEFA and
packaging into TG-rich lipoproteins. Contrary to this hypothesis, we found that when
peripheral TG uptake was blocked by treatment with P-407, CL316,243 actually
decreased the rate of hepatic TG secretion and lowered plasma TG (Figure 2.6 C,D).
These data indicate that CL316,243 increases plasma TG by delaying LPL-dependent
clearance, rather than by increasing hepatic TG secretion.
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2.3.7. Inhibiting lipolysis restores plasma TG levels increased by rapamycin treatment
We next investigated whether inhibiting adipocyte lipolysis in vivo is sufficient to reverse
rapamycin-induced hyperlipidemia. Wildtype mice were treated with rapamycin (2 mg/kg
daily by intraperitoneal injection) for 2 weeks to induce hypertriglyceridemia. To inhibit
lipolysis selectively in adipose tissue, we used a GPR81 agonist (3Cl-5OH-BA). GPR81
is predominantly expressed in adipose tissue, and physiological activation of this
receptor by lactate leads to suppression of lipolysis (Ge et al., 2008; Sakurai et al.,
2014). This approach avoids inhibiting hepatic ATGL, which complicates the
interpretation of experiments targeting that enzyme pharmacologically. As expected,
rapamycin-treated mice failed to fully suppress plasma NEFA levels upon refeeding, and
this was corrected by treatment with the GPR81 agonist (Figure 2.7A). In parallel, the
GPR81 agonist restored refed plasma TG to control levels (Figure 2.7B). These results
indicate that restoring adipocyte lipolysis to normal levels can mitigate rapamycininduced hypertriglyceridemia.
2.4 Discussion
Although mTORC1 is known to influence lipid metabolism through multiple pathways in
multiple cell types, the precise etiology of hyperlipidemia induced by systemic mTORC1
inhibition in vivo remains uncertain. Indeed, genetic loss of mTORC1 in hepatocytes
causes the opposite phenotype, lowering circulating cholesterol and TG (Peterson, T. R.
et al., 2011; Quinn et al., 2017). Here we show that loss of mTORC1 in adipocytes is
sufficient to cause hypertriglyceridemia despite having only modest effects on the
expression and ex vivo activity of lipoprotein lipase. Mechanistically, we show that
although mTORC1 signaling affects many aspects of adipocyte biology,
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hypertriglyceridemia is driven primarily by unrestrained lipolysis in the fed state, which
likely interferes with the in situ activity of lipoprotein lipase.
Studies in cultured adipocytes have demonstrated that that inhibition of mTORC1
signaling with rapamycin leads to increased lipolysis in response to b-adrenergic
stimulation via enhanced HSL phosphorylation (Soliman et al., 2010), and more
generally via activation of Egr1-dependent ATGL transcription (Chakrabarti et al., 2010;
Chakrabarti et al., 2013). Here, we show that genetic deletion of ATGL in adipocytes is
sufficient to normalize refed NEFA and TG levels in RaptoraKO mice, supporting a model
in which lipolysis drives hypertriglyceridemia. However, we did not observe a significant
increase in ATGL protein expression in adipose depots of RaptoraKO mice, consistent
with several other studies (Lee, P. L. et al., 2016; Lopes et al., 2014; Pereira et al., 2013;
Soliman et al., 2010). This suggests that ATGL expression per se cannot account for the
increase in lipolysis. A more general mechanism that can account for the widespread
effects of Raptor deletion on lipid metabolism and might contribute to increased lipolysis
is the suppression of PPARg and C/EBPa transcriptional activity in the absence of
mTORC1 (Blanchard et al., 2012; Kim, J. E. & Chen, 2004; Lee, P. L. et al., 2016). The
phenotypes of adipose-specific C/EBPa KO mice are complicated by severe
lipodystrophy early in life, but we note that these animals exhibit impaired TG clearance
(Chatterjee et al., 2011). Germline ablation of the C/EBPa target Plin1 (encoding
perilipin 1) mimics the lipolytic phenotype of RaptoraKO mice; these animals have
increased basal lipolysis and decreased stimulated lipolysis (Tansey et al., 2001).
Moreover, decreased expression of Plin1 is observed in mice treated with rapamycin
(Pereira et al., 2013) and in RaptoraKO mice (Supplementary Figure 2.3F). Perilipin 1
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coats the outside of lipid droplets to prevent hydrolysis by ATGL. Thus, a decrease in
perilipin 1 expression is one mechanism that could account for an increase in ATGLdependent lipolysis in the absence of a change in ATGL expression.
A number of prior studies have implicated decreased adipose LPL in the
hypertriglyceridemia associated with rapamycin treatment (Blanchard et al., 2012;
Kraemer et al., 1998; Morrisett et al., 2003; Pereira et al., 2013; Tory et al., 2008).
Consistent with these reports, we observed a decrease in LPL gene expression, and
showed that TG clearance, but not hepatic production of TG-rich lipoproteins, is altered
in RaptoraKO mice. However, we were able to detect only small decreases in the LPL
activity that could be released by heparin in vivo or extracted from adipose tissue.
Moreover, deletion of ATGL restored TG clearance without correcting Lpl gene
expression. LPL activity has been shown to be inhibited by ANGPTL4, in vitro and in
vivo, which could account for differences in activity vs. expression (Koster et al., 2005;
Sukonina et al., 2006). However, we were unable to detect consistent changes in
Angptl4 expression in RaptoraKO mice, regardless of ATGL status (Supplementary Figure
2.3F). Another possibility to explain the disconnect between LPL expression and activity
is inhibition due to local accumulation of NEFA and MG. It has long been appreciated
that NEFA can suppress LPL through multiple mechanisms, including product inhibition,
displacement of the active enzyme from the endothelium, and preventing its interaction
with activating factors such as ApoC-II (Amri et al., 1996; Gordts et al., 2016; Peterson,
J. et al., 1990; Saxena et al., 1989). As a “proof of principle” experiment for this
mechanism, we stimulated adipose tissue lipolysis with a b-adrenergic agonist and
showed that this was sufficient to delay TG clearance in an oral fat tolerance test.
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Similarly, a GPR81 agonist that suppresses adipocyte lipolysis was sufficient to acutely
normalize plasma TG in rapamycin-treated mice. Notably, acute dosing with niacin has
been reported to suppress postprandial hypertriglyceridemia in humans, and it was
speculated that this might be related to a reduction in NEFA release from adipose
(Montserrat-de la Paz et al., 2018; Usman et al., 2012). Thus, we propose that
inappropriate lipolysis in the fed state directly impairs LPL activity in RaptoraKO mice, and
that such inhibition may be a general feature of hyperlipidemia.
An interesting aspect of the elevated NEFA and TG phenotypes of RaptoraKO mice is
their complete dependence on feeding status. This may provide an explanation for
conflicting reports on the effect of rapamycin on NEFA, which have been significantly
increased in some studies and decreased in others (Blanchard et al., 2012; Fang et al.,
2018; Fang et al., 2013; Houde et al., 2010; Lopes et al., 2014). It also makes clear that
impaired adipocyte mTORC1 signaling is not the only factor contributing to rapamycininduced hyperlipidemia, since circulating TG levels in rapamycin-treated animals are not
completely resolved by fasting. In part, this may reflect the ability of rapamycin to reduce
LPL expression in tissues such as skeletal and cardiac muscle that play a larger role in
TG clearance during fasting. We also note that chronic rapamycin treatment can impair
mTORC2 activity; as mice lacking mTORC2 in adipose tissue have a defect in insulindependent suppression of lipolysis, both mTOR complexes may act together to fully
restrain adipocyte lipolysis (Kumar et al., 2010). Consistent with a role for mTORC2 in
rapamycin-induced hyperlipidemia, it was recently shown that a rapamycin derivative
that avoids mTORC2 inhibition (DL001) also fails to induce hyperlipidemia in fasted mice
(Schreiber, K. H. et al., 2019). The effect of DL001 on TG in fed mice has not been
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reported. Finally, although our data suggest that lipolysis can affect plasma cholesterol
levels, it is unclear whether this is directly related to LPL activity, and further study will be
required to fully elucidate the mechanism and the degree to which loss of adipocyte
mTORC1 recapitulates the hypercholesterolemic effects of rapamycin.
We demonstrate that mTORC1 signaling in adipose tissue is critical for the maintenance
of plasma lipid homeostasis in the fed state. Lack of mTORC1 in adipocytes increases
both lipolysis and circulating TG in fed mice. Lipolysis is causally related to
hypertriglyceridemia, since genetic ablation of ATGL resolves both circulating NEFA and
TG clearance rates. Moreover, direct stimulation of lipolysis in wild type mice is sufficient
to impair TG clearance. Thus, mTORC1-dependent suppression of adipocyte lipolysis is
an essential switch to maintain plasma lipid concentrations during feeding.
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Figure 2-1. Adipocyte-specific ablation of mTORC1 elevates plasma lipids prior to
lipodystrophy.
(A) Western blot for Raptor in IWAT, EWAT, BAT and liver. Numbers indicate relative
density normalized to β-actin. (B) Western blot of downstream mTORC1 substrates in
IWAT, EWAT, and BAT of RaptoraKO and Raptorfl/fl littermates. (C) Body and (D) tissue
weights with age of male RaptoraKO mice compared to controls (male, n=3-11). (E)
Tissue weights and (F) random fed plasma lipid parameters of 10-week-old RaptoraKO
mice (n=6-9). Data presented as mean ± s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 2-2. Adipocyte-specific ablation of mTORC1 elevates plasma lipids upon
refeeding.
10-week-old Raptorfl/fl and RaptoraKO mice were fasted overnight and refed. (A) Plasma
TG (n=8-10). (B) Plasma NEFA (n=8-10). (C) Mice were fasted (n=5) or fasted and refed
(n=3-4) as described in methods and plasma TG was measured at indicated time points
after injection with P-407 to measure hepatic TG secretion. (D) Mice were fasted and
plasma TG was measured at indicated time points during an oral fat tolerance test to
measure clearance of circulation TG (n=6-8). Data presented as mean + s.e.m. *p <
0.05, **p < 0.01, ***p < 0.001.
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Figure 2-3. Adipocyte-specific ablation of mTORC1 causes a modest deficiency in
lipoprotein lipase.
(A) Lpl gene expression normalized to TBP for IWAT, EWAT, BAT and skeletal muscle
from refed 10-week-old Raptorfl/fl and RaptoraKO mice (n=4-6). (B) Post-heparin plasma
LPL activity in the fasted and refed state (n=6). (C) Tissue LPL activity for IWAT, EWAT,
BAT and skeletal muscle (n=4). Data presented as mean + s.e.m. *p < 0.05, **p < 0.01,
***p < 0.001.
Figure 3

A

B

400

100

1.0

**
0.5

0.0

***

IWAT EWAT BAT SM-Gas

75
50

*

25

LPL Activity (mUnits/g)

RaptoraKO

Lpl Gene Expression

C
125

Raptorfl/fl

Post Heparin Plasma LPL Activity
(mUnits/mL)

1.5

350
300
250

*

**

200
150
100
50

0

Fasted

62

Refed

0

IWAT EWAT BAT SM-Gas

Figure 2-4. Adipocyte-specific ablation of mTORC1 alters intracellular lipids.
10-week-old Raptorfl/fl and RaptoraKO mice were fasted overnight and refed for 4 h prior to
collection of EWAT for lipidomics. Fold change in relative abundance compared to
Raptorfl/fl for (A) NEFA, (B) monoacylglycerols (MG), (C) diacylglycerols (DG), and (D)
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method. (E) Total ion counts from (A-D). (F) Plasma glycerol (n=3-6). Data presented as
mean + s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 2-5. Genetic inhibition of lipolysis reverses lipid phenotypes of adiposespecific mTORC1 KO.
10-week-old mice were fasted overnight and refed. (A) Diagram of the lipolysis pathway.
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Figure 2-6. Increased plasma NEFA from lipolysis delays clearance of plasma TG.
(A, B) Male C57BL/6 mice were fasted overnight and gavaged with olive oil for an oral
fat tolerance test. Mice were injected with either saline or CL316,243 at 1 hour (arrow).
(A) Plasma NEFA and (B) plasma TG were measured at the indicated time points (n=56). (C, D) Mice were fasted overnight and refed then injected with P-407 to measure
hepatic TG secretion. Either saline or CL316,243 was injected at 1 hour (arrow). (C)
Plasma NEFA and (D) plasma TG was measured at indicated time points after P-407
Figure 6 injection. Data presented as mean + s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 2-7. Inhibiting lipolysis restores plasma TG levels in rapamycin treated
mice.
Male C57BL/6 mice were treated with 2mg/kg rapamycin for 2 weeks to induce
hyperlipidemia. Mice were fasted overnight then injected with 100 mg/kg GPR81 agonist
at the time of refeeding. (A) Plasma NEFA and (B) plasma TG were measured at 0, 0.5
and 3 h after refeeding. Data presented as mean + s.e.m. Compared to rapamycin
treatment, *p < 0.05, **p < 0.01, ***p < 0.001.
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Supplementary Table 2-1. EWAT lipidomics ion counts for Raptorfl/fl and RaptoraKO
mice.
Data presented as mean + s.e.m. for each genotype (n=5-6). Two-tailed unpaired t-test.
P-value prior to multiple comparison and adjusted p-value corrected for multiple
comparison using the Holm-Sidak method.
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Supplementary Figure 2-1. Adipocyte-specific ablation of mTORC1 elevates
plasma lipids prior to lipodystrophy.
(A-C) Relative density of western blots from Figure 1B (n=2). (D) Body and (E) tissue
weights with age of female RaptoraKO mice compared to controls (n=4-15). (F) Immune
cell
gene
Figure
S1 expression in EWAT from 10 week old males (n=5). Random fed plasma TG
from females (G) and males (H) (females n=4-12, males n=6-10). (I) Liver TG from male
RaptoraKO mice compared to controls at 3 and 12 months (Raptorfl/fl n=5-10,
RaptoraKO n=6). Data presented as mean + s.e.m. Two-tailed unpaired t-test. *p < 0.05,
**p < 0.01, ***p < 0.001.
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Supplementary Figure 2-2. Adipocyte-specific ablation of mTORC1 elevates
plasma lipids upon refeeding.
10-week-old Raptorfl/fl and RaptoraKO mice were fasted overnight and refed. (A) Change
in body weight with refeeding and (B) Blood glucose (n=8-10). Data presented as mean
+ s.e.m. Two-tailed unpaired t-test. *p < 0.05, **p < 0.01, ***p < 0.001.
Figure S2

10

Raptorfl/fl

Body Weight % Change

RaptoraKO
8

6

4

2

0

B
Blood Glucose (mg/dL)

A

150

100

50

0

71

Fasted

Refed

Supplementary Figure 2-3. Genetic inhibition of lipolysis reverses lipid
phenotypes of adipose-specific mTORC1 KO mice.
(A) Western blot of Raptor and ATGL protein in liver (n=2). 10-week-old mice were
fasted overnight and refed. (B) Body weight and (C) IWAT, EWAT, BAT and liver weight
as percent body weight (n=3-6). (D) Refed plasma cholesterol (n=3-9). (E) Lpl gene
expression from IWAT, EWAT and Bat (n=6-8). (F) Cgi-58, Plin1 and Angtpl4 gene
expression from EWAT (n=5). Data presented as mean + s.e.m. Two-way ANOVA
Figure
S3
corrected
for multiple comparisons using the Tukey method. * = p < 0.05, ** = p < 0.01,
*** = p < 0.001.
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Mice were fasted overnight and gavaged with olive oil for an oral fat tolerance test. All
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TG were measured at the indicated time points. Data presented as individual data
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CHAPTER 3: Loss of mTOR signaling in adipose tissue does not
solely account for the hyperlipidemia induced by rapamycin
treatment
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3.1 Abstract
Rapamycin has been shown to expand median and maximal life span in mice, yet
induces hyperlipidemia. Raptor and Rictor are essential component of mechanistic target
of rapamycin (mTOR) complex 1 (mTORC1) and 2 (mTORC2), respectively. Loss of
mTORC1 signaling in adipose is sufficient to disrupt lipid homeostasis, resulting in
hyperlipidemia caused by unrestrained lipolysis. However, studies to date examining the
role of deletion of this complex, complex 2 or both in adipose tissue in combination with
rapamycin have yet to be investigated. Here, we report the consequences of Raptor,
Rictor or both deleted specifically in mature adipocytes driven by Adiponectin-Cre
(RaptoraKO, RictoraKO, Raptor-RictoraKO). Concordant with the RaptoraKO mice, RictoraKO
mice display pronounced hyperlipidemia and both KO models have a further increase in
plasma lipids with rapamycin treatment. Genetic inhibition of lipolysis in mice with loss of
mTORC1 (ATGL-RaptoraKO) treated with rapamycin prevents the further increase in
plasma lipids seen in Raptorako mice treated with rapamycin. We propose a general
mechanism that in the fed state, rapamycin inhibition of adipose mTORC1 leads to
decreased C/EBPa transcriptional activity. This decreased transcriptional activity results
in decreased expression of perilipin and subsequent unrestrained lipolysis, leading to
hyperlipidemia.
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3.2 Introduction
Rapamycin has recently been shown to increase life span and delay age related
changes in mice, raising the possibility that it could be more broadly useful in humans.
However, there are metabolic side effects associated with rapamycin treatment that
pose significant challenges to its therapeutic use for age-related effects in otherwise
healthy individuals. The mechanism(s) by which rapamycin treatment causes
hypercholesterolemia and hypertriglyceridemia are not known. Hyperlipidemia is a major
risk factor for cardiovascular diseases due to the acceleration of plaque formation. The
use of lipid-lowering drugs in combination with rapamycin does not reduce fasting
plasma cholesterol levels below the recommended target level (Firpi et al., 2004; Lisik et
al., 2007). Understanding how rapamycin treatment causes the adverse side effects of
elevated plasma cholesterol and TGs will improve our basic understanding of lipid
metabolism and allow the development of strategies to mitigate this process and to
make use of the therapeutic properties of rapamycin in humans
The discovery of rapamycin’s antiproliferative and immunosuppressive properties
provoked a significant effort to identify the mode of action. This lead to the identification
of target of rapamycin (TOR) proteins in yeast in 1991 and identification of their
mammalian counterpart, known as mechanistic target of rapamycin (mTOR) in 1994
(Chiu et al., 1994; Sabatini et al., 1994). mTOR is a Ser/Thr protein kinase that controls
cell growth and metabolism. mTOR nucleates two structurally and functionally distinct
complexes, mTORC1 (characterized by the presence of raptor) and mTORC2
(characterized by the presence of rictor). mTORC1 is the canonical target of rapamycin
and is acutely inhibited by the drug, whereas mTORC2 is not affected by short-term
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exposures (up to several hours). In 2012, the Baur and Sabatini labs demonstrated that
chronic rapamycin treatment disrupts mTORC2 assembly in liver, white adipose tissue
and skeletal muscle in vivo, suggesting a second molecular mechanism of rapamycin
effects (Lamming et al., 2012; Schreiber, K. H. et al., 2015).Tissue specific disruption of
mTORC1 or mTORC2 has revealed that each complex has different effects on whole
body glucose and lipid homeostasis in different organs (Kennedy & Lamming, 2016).
Recent studies have revealed that mTOR signaling is critical in the regulation of
adipose tissue function, including roles in adipogenesis, lipid metabolism and
thermogenesis. We have previously reported the effects of adipose mTORC1 KO mice.
Loss of adipose mTORC1 signaling increased plasma cholesterol, TG and NEFA and
this effect is dependent on the fed state. In addition, we showed that the increase in
plasma TG is caused by a failure to restrain adipose lipolysis, as mice with genetic
inhibition of lipolysis restores plasma TG levels in RaptoraKO mice. A more general
mechanism that we propose to account for the widespread effects of Raptor deletion on
lipid metabolism and might contribute to increased lipolysis is the suppression of
C/EBPa transcriptional activity (Blanchard et al., 2012; Kim, J. E. & Chen, 2004; Lee, P.
L. et al., 2016).
mTORC2, defined by the presence of the essential subunit Rictor (rapamycininsensitive companion of mTOR) was more recently discovered and remains less well
understood. Loss of mTORC2 function in the whole body, liver, or adipose tissue has
been reported to disrupt glucose homeostasis, whereas its loss in skeletal muscle has
comparatively mild effects. mTORC2 has emerged as a key controller of lipid
metabolism in the liver and adipose tissue, but the mechanisms involved have yet to be
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determined. Two studies that have examined the role of this complex in mature
adipocytes both relied on aP2/fabp4-Cre, which can have off-target effects in
macrophages and neurons that complicate the interpretation of phenotypes (Cybulski et
al., 2009; Kumar et al., 2010). These groups observed profound hyperinsulinemia and
insulin resistance, impaired suppression of lipolysis, and an increase in body and organ
size that was attributed to an increase circulating IGF1. In contrast, deletion of Rictor in
adipocyte precursors using Myf5-Cre was found to protect mice from obesity, enhance
oxidative metabolism in brown adipocytes, and to promote the formation of smaller,
multilocular cells resembling brown/beige adipocytes in white adipose depots (Hung et
al., 2014). Two important caveats to this study were that effects on differentiation could
not be separated from effects on mature adipocytes, and that loss of Rictor was mosaic
in white adipose depots. Highlighting the importance of the timing of deletion, Albert et
al. showed that in mature brown adipocytes (Ap2-Cre driven deletion) mTORC2dependent glucose uptake was required to sustain thermogenesis (Albert et al., 2016).
Impressively, treatment with rapamycin can begin as late as 600 days in mice,
which is comparable to 60 years of age in humans, suggesting that rapamycin may be
able to treat age-related diseases and improve health in middle-aged humans. The
effects of rapamycin on longevity are not restricted to cancer and immune effects. For
instance, mTORC1 inhibition with rapamycin promotes the degradation of aggregateprone proteins in vitro, reduces the severity of neurodegeneration in vivo, reducing the
aggregation of misfolded proteins by slowing protein synthesis and/or promoting
autophagy (Caccamo et al., 2010; Spilman et al., 2010). This suggests that mTORC1
signaling may play a role in the development of these pathologies. In fact, mTOR is
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frequently dysregulated in human diseases, including cancer, obesity and type 2
diabetes and neurodegeneration. However, the use of rapamycin as a therapeutic for
aging and age related diseases is limited by the hyperlipidemia and other metabolic side
effects. This study will expand our knowledge on mTOR signaling in adipose tissue and
the role of adipose tissue in metabolic dysregulation, and provide a mechanistic
understanding of the hyperlipidemia seen with rapamycin treatment. Ultimately, this work
has the potential to lead to improved therapeutic uses of rapamycin to improve quality of
life for patients receiving the drug and to allow its use for the prevention or delay of agerelated disorders in otherwise healthy people.
3.3 Results
3.3.1. Two weeks of rapamycin treatment in mice is sufficient to recapitulate the increase
in plasma lipids that is seen in human.
It has been shown that rapamycin increase plasma lipids in mice, as in humans.
However, it remains unclear whether the low doses of rapamycin used for most of
longevity studies induces the same metabolic changes associated with higher doses.
Therefore, a lower dose was used in this study to tested whether our method can
recapitulate the effects seen in humans. Using a dose of 2mg/kg rapamycin, which is
similar to the doses used in aging studies, in a .25% Peg400/Tween80 vehicle in male
mice, we showed that this 2 weeks of treatment does not affect body weight of tissues
weights (Figure 3.1 A,B). In addition, rapamycin treatment was able to increase plasma
lipids, including cholesterol (both HDL and non-HDL cholesterol), TG, phospholipids (PL)
and NEFA (Figure 1C). In human studies, rapamycin increases different apolipoproteins.
Although we did not test the different apolipoproteins in rapamycin treated me, we
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performed FPLC on plasma to separate the different lipoproteins into fractions in order to
measure the cholesterol and TG concentrations (Figure 1D). Rapamycin treatment
increase lipids in CM/VLDL (5-10 fractions), IDL/LDL (15-30 fractions) and HDL (30-45
fractions). Since the plasma for FPLC was pooled from multiple mice, statistics cannot
be quantified. However, the area under the curve for each fraction showed an increase
in both plasma cholesterol and TG (Figure 1 E,F). Therefore, we verified that our
rapamycin treatment protocol successful induces hyperlipidemia, comparable to
increase in human patients.
3.3.2. Rapamycin treatment increases plasma lipids in adipose-specific mTORC1 KO.
We have previously shown that deletion of mTORC1 in adipose tissue induces
hyperlipidemia comparable to rapamycin treatment alone, we wanted to investigate
whether mTORC1 adipose KO mice respond to rapamycin treatment. Previous
treatments of RaptoraKO mice with rapamycin in the random fed state have resulted in
various changes in lipids. Since we have shown the hyperlipidemia phenotype in
RaptoraKO mice is dependent on feeding status, we treated 5-month-old females with
rapamycin and measured plasma lipids after fasting and refeeding. For refed plasma
cholesterol, TG and NEFA, rapamycin increased plasma lipids comparable to mTORC1
KO alone. However, the combination of rapamycin treatment and loss of adipose
mTORC1 further increased plasma lipids compared to either rapamycin of mTORC1 KO
alone (Figure 3.2 A-C). In the fasted state however, only plasma TG were increased in
rapamycin treated mice not in RaptoraKO as previously shown. In addition, we performed
FPLC on random fed RaptoraKO mice treated with rapamycin on age matched mice from
figure 3.1. The plasma cholesterol and TG from the different fractions recapitulates the
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total plasma lipids from figure 3.2 A and B (Supplementary Figure 3.1 A). The area
under the curve for each fraction is compared to the results from figure 3.1 E and F
(Supplementary Figure 3.1 A,C). This suggestion that in the fasted state, the effects of
rapamycin on plasma lipids is independent of adipose mTORC1. These results indicate
that adipocyte mTORC1 inhibition is only partially responsible for the hyperlipidemic
effect of rapamycin, and that other factors also play a role.
3.3.3. Adipocyte-specific ablation of mTORC2 elevates plasma lipids upon refeeding.
One of the factors that may contribute to rapamycin’s effects is the inhibition of
mTORC2. In fact, mTORC2 in adipose tissues has also been shown to regulate various
aspects of growth and metabolism in response to nutrient and energetic stimuli.
Therefore, we tested whether mTORC2 in adipose tissue contributes to rapamycin’s
effects. To test this, we generate adipose specific rictor knockout mice, we crossed mice
in which the rictor gene were flanked by loxP sites (Rictorfl/fl) to mice expressing cre
recombinase under the control of the adipose specific adiponectin gene promoter
(RictoraKO). As expected, these mice lacked rictor specifically in adipose depots including
inguinal, visceral, and brown adipose while maintaining expression in non-targeted
tissues such as the liver (Figure 3.3 A). Body weight of RictoraKO mice was monitored
from 3 to 12 weeks of age. The weight of both male and female RictoraKO mice (females
no shown) was equal to their littermate controls (Figure 3.3 B). Since RaptoraKO mice
have decreased tissue weights after 12 weeks, we measured tissue weights from 5month-old males in the refed state. Overall, there was an increase in the weight of the
liver in male mice, while the adipose depots were equal to littermate controls (Figure 3.3
C). Interestingly, there was a trend towards decreased fat weight in the inguinal depot
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but did not reached significance. To further investigate whether loss of mTORC2 in
adipose also induces hyperlipidemia, we measured plasma lipids after an overnight fast
and 4 hour refed. Comparable to the mTORC1 adipose KO mice, plasma cholesterol,
TG and NEFA were significantly increased in the refed state (Figure 3.3 D-F). In
addition, loss of mTORC2 in adipose had no effect on fasting plasma TG levels.
Contrary to RaptoraKO mice, fasting plasma NEFA levels were comparable to littermate
controls. We next tested whether the addition of rapamycin treatment would increase
plasma lipids in RictoraKO. As with RaptoraKO, rapamycin increased plasma cholesterol
and TG to levels comparable to RictoraKO alone. However, rapamycin further increased
plasma lipids levels in RictoraKO compared to rapamycin or RictoraKO alone (Figure 3.3 G).
These results indicate that loss of mTORC2 signaling in adipose tissue is only partially
responsible for the lipid effects of rapamycin treatment.
3.3.4. Rapamycin treatment further increases plasma lipids in adipose-specific mTORC1
and mTORC2 KO mice.
Since loss of either mTORC1 or mTORC2 in adipose tissue only partially contributes to
rapamycin associated hyperlipidemia, we next asked whether inhibition of both
complexes is necessary to induce the hyperlipidemia. To investigate whether inhibition
of both mTORC1 and mTORC2 accounts for the effects of rapamycin treatment on
plasma lipids, we crossed the RaptoraKO mice with Rictorfl/fl mice. Since RaptoraKO mice
develop lipodystrophy after 12 weeks, were used Raptor-RictoraKO mice and littermate
controls prior to 12 weeks of ago. Loss of both complexes in adipose did not affect body
weight or blood glucose (Figure 3.4 A,B). Comparable to either KO alone, RaptorRictoraKO had increase plasma cholesterol both in the fasted and refed state, and
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increased plasma TG in the refed state (Figure 3.4 C,D). Fasting plasma NEFA were
decreased compared to controls, similar to RaptoraKO alone. However refed plasma
NEFA were increased but did not reach statistical significance. Surprisingly, fasting
plasma TG were decreased in Raptor-RictoraKO. Despite that these results indicate that
inhibition of both complexes contribute the unrestrained lipolysis caused by rapamycin
treatment, loss adipose tissue mTOR signaling only partially contributes to the increased
TG effects of rapamycin treatment.
3.3.5. Genetic inhibition of lipolysis reverses lipid phenotypes of adipose-specific
mTORC1 KO treated with rapamycin.
We have previously determined that genetic inhibition of lipolysis reverses plasma lipid
increases in RaptoraKO mice. Previous lipidomics results showed that loss of adipose
mTORC1 increases EWAT MG, DG, and TG species. Genetic inhibition of lipolysis in
RaptoraKO mice (ATGL-RaptoraKO), was able to prevent the increase in EWAT DG and
TG species, suggesting that the increased lipolysis in RaptoraKO mice resulted in
increased intracellular DG and TG levels (Figure 3.5 A). However, ATGL-RaptoraKO did
not prevent the increase in intracellular MG species, suggesting that loss of adipose
mTORC1 may alter intracellular lipid processes other than lipolysis (i.e. esterification).
We have previously shown that short term inhibition of lipolysis prevents increases in
plasma TG in rapamycin treated mice. To investigate whether the confounding effects of
long term deleting of adipose mTORC1 accounts for the further increase on plasma
lipids with rapamycin treatment, we treated ATGL-RaptoraKO mice with rapamycin for 2
weeks. Plasma cholesterol, TG and NEFA levels in RaptoraKO mice treated with
rapamycin were significantly increased compared to vehicle, rapamycin, ATGLaKO +
83

rapamycin and ATGL-RaptoraKO + rapamycin (Figure 3.5 B-D). Interestingly, ATGLaKO
mice treatment with rapamycin did not significantly increase plasma lipids compared to
the vehicle treated mice. Although the ATGL-RaptoraKO mice treatment with rapamycin
had increased levels compared to vehicle treated mice, plasma lipids were comparable
to rapamycin treatment alone. These results suggest that although long term loss of
adipose mTORC1 and the concurrent unrestrained lipolysis is responsible for the
additive effect of rapamycin on plasma lipids. Whether acute or long term inhibition, how
loss of mTORC1 signaling leads to unrestrained lipolysis is still under debate.
3.3.6. General mechanism for the widespread effects of Raptor deletion on lipid
metabolism.
We have previously proposed a potential mechanism were suppression of C/EBPa
transcriptional activity and decreased perilipin may account for the for the widespread
effects of Raptor deletion on lipid metabolism. To test this hypothetical mechanism, we
first measured C/EBPa expression. As expected, C/EBPa gene expression is decreased
in refed male RaptoraKO mice (Figure 3.6 A). We next examined protein expression in
IWAT of these mice. In line with gene expression, both p30 and p42 isoforms of C/EBPa
protein was decreased compared to littermate controls (Figure 3.6 B,C). This supports
our hypothesis that RaptoraKO have decreased C/EBPa transcriptional activity and thus
decreased expression of lipid metabolism genes regulated by C/EBPa. We have
previously shown decreased perilipin gene expression. To investigate whether
decreased gene expression results in decreased perilipin protein levels, we measured
perilipin proteins expression by western blot from IWAT of RaptoraKO mice (Figure 3.6D).
Perilipin protein expression was quantified from two different exposures, both
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quantification yielded the same decrease in protein levels (Figure 3.6 E). In addition,
when lipolysis is stimulated in the fasting condition or with the b3-adrenergic agonist of
CL 316,243, perilipin is phosphorylated. CL 316,243 treatment successful stimulated
phosphorylation of perilipin on Ser522 (Figure 3.6F). However, when RaptoraKO mice are
treated with CL 316,243, phosphorylation does not increase. This data indicates that the
increased lipolysis associated with suppression of C/EBPa transcriptional activity or
decreased perilipin expression may contribute to the lipid phenotype of the RaptoraKO
mice.
3.4 Discussion
Rapamycin is known to induce hyperlipidemia in organ transplant patients within 2
weeks of treatment. The doses of rapamycin used to test longevity varies from study to
study, ranging from 1.5mg/kg to 4mg/kg when injected and around 2.24mg/kg when
encapsulated in food at 14ppm, with some studies using up to 42ppm (Anisimov et al.,
2011; Harrison et al., 2009; Miller et al., 2011; Miller et al., 2014; Neff, F. et al., 2013;
Zhang, Y. et al., 2014). A lower dose of rapamycin was used in this study, which was
able to induce hyperlipidemia within 2 weeks. This hyperlipidemia includes increase in
plasma cholesterol, TG, NEFA as well as phospholipids. The increases in total plasma
cholesterol and TG is associated with increases in the lipid content of the different
lipoproteins, CM/VLDL, the TG-rich lipoproteins, as well as LDL and HDL fractions, in
both rapamycin treated animals and RaptoraKO mice. Although this does not imply
whether production or degradation of these lipoproteins is effected, we have previously
demonstrated that production of VLDL by the liver is not increased but rather clearance
of TG-rich lipoproteins is decreased.
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We first hypothesized that loss of mTORC1 signaling in adipose tissue mediates
the effects of rapamycin treatment. However, our mTORC1 adipose KO mice had further
increased plasma lipids when treated with rapamycin. Since plasma lipids of rapamycin
treated mice are comparable to RaptoraKO alone, we speculated that the long term
genetic deletion of raptor in these mice is responsible for the exacerbated effects with
rapamycin. In fact, when we restored plasma lipids levels of RaptoraKO with genetic
inhibition of lipolysis (ATGL-RaptoraKO), and treated these mice with rapamycin, the
additional increase in lipids seen in RaptoraKO is prevented, yet lipid levels are still
comparable to rapamycin treatment alone. We speculate that pre-existing effects of the
loss of adipose mTORC1 prior to rapamycin treatment is responsible for the further
increase in plasma lipids seen. It is important to note that ATGLaKO mice do not respond
to rapamycin. This supports our previous finding that short term lipolysis inhibition with
GPR81 agonist (3Cl-5OH-BA) prevents the increase in plasma TG seen with rapamycin
treatment.
Chronic rapamycin treatment can also impair mTORC2 activity, as mice lacking
mTORC2 in adipose tissue have a defect in insulin-dependent suppression of lipolysis.
We generated and measured plasma lipids in RictoraKO mice under fast refed conditions
to determine if the loss of rictor in adipose tissue had an effect on these parameters.
Plasma cholesterol, TG, and NEFA were significantly increased in RictoraKO mice
compared to littermate controls in the refed state, while fasted NEFA levels remained the
same. This is the only lipid phenotype that differs from our RaptoraKO mice. However,
mTORC2 adipose KO mice also respond to rapamycin. Kumar et al suggested that both
mTOR complexes may act together to fully restrain adipocyte lipolysis (Kumar et al.,
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2010). Our results from inhibition of both mTORC1 and mTORC2 in adipose supports
this, as all refed plasma lipids were significantly increased in this double KO compared
not only to control mice but to each KO individually. We speculate that inhibition of
lipolysis, using our genetic model or a short term lipolysis inhibitor, would also reverse
the increase in plasma lipids in Raptor-RictoraKO mice. However, we were unable to test
this due to poor breeding associated with rictor genetic models. We did demonstrate that
rapamycin treatment in combination with loss of both complexes in adipose tissue still
increases plasma lipids. However, this exacerbated effect may be caused from long term
loss of mTOR signaling.
Importantly, it should be noted that rapamycin treatment increased fasting
plasma TG levels, where the effect of mTORC1 deletion does not. This suggest an effect
of rapamycin on an organ other than adipose in the fasting setting. More investigation,
most likely on the muscle is needed to identify the cause of increased fasting plasma
TG. In addition, it was recently shown that a rapamycin derivative that avoids mTORC2
inhibition (DL001) also fails to induce hyperlipidemia in fasted mice (Schreiber, K. H. et
al., 2019). Therefore, we hypothesize that, in the fed state, the effects of loss of adipose
mTORC1 account for the for the widespread effects of rapamycin on lipid metabolism.
This general hypothesis stems from changes in two key lipid metabolism proteins,
C/EBPa and its transcription control of key metabolism genes, and perilipin, the lipid
droplet protein that coats the droplet layer prevent access to ATGL, the rate limiting
enzyme in lipolysis. Here, we show that protein expression for both C/EBPa and perilipin
are decreased in mice with loss of adipose mTORC1. Adipose-specific C/EBPa KO mice
not only exhibit impaired TG clearance, but develop lipodystrophy (Chatterjee et al.,
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2011), although this phenotype develops earlier in life than the lipodystrophy in
RaptoraKO mice. One target of C/EBPa transcriptional control is Plin1 (encoding perilipin
1). We previously showed decreased gene expression, and have now shown decreased
protein expression of perilipin. Decreased perilipin protein leads to an increase in access
of ATGL to the lipid droplet, which is normally inhibited in the fed state. As well as
decreased levels of protein to be phosphorylated when lipolysis is activated in the fasted
state. The latter explains the decrease in fasting plasma NEFA levels in the RaptoraKO
mice. Since adipose perilipin KO mice mimic the lipid phenotype of RaptoraKO mice,
increased basal lipolysis and decreased stimulated lipolysis (Tansey et al., 2001), and
mice treated with rapamycin (Pereira et al., 2013) have decreased expression of Plin, we
propose that in the fed state, rapamycin inhibition of adipose mTORC1 leads to
decreased C/EBPa transcriptional activity. This decreased transcriptional activity results
in decreased expression of perilipin and subsequent unrestrained lipolysis, leading to
hyperlipidemia.
Together, these studies reveal a number of important roles for mTORC1 and
mTORC2 in adipose tissue based on feeding status and effects of rapamycin
independent of these two complexes in adipose tissue. of suggest that its activation
might have a therapeutic effect in metabolic disorders.
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Figure 3-1. Mice treated with rapamycin for 2 weeks recapitulates the increases in
human plasma lipids.
4-month-old male C57BL/6 mice were treated with 2mg/kg rapamycin for 2 weeks to
induce hyperlipidemia. (A) Body weight and (B) tissue weights after 2 weeks of vehicle
(n=10) or rapamycin (n=11). treatment. (C) Random fed plasma lipids panel from n=6
control and n=8 rapamycin mice. (D). FPLC TG and cholesterol profiles of pooled
plasma from the remaining control (n=4) and rapamycin (n=3). (E) Plasma cholesterol
and (F) plasma TG AUC. (A-C) Data presented as mean ± s.e.m. *p < 0.05, **p < 0.01,
***p < 0.001. (D-F) Data presented as a single value from pooled samples.
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Figure 3-2. Rapamycin treatment further increases plasma lipids in adiposespecific mTORC1 KO.
5-month old female Raptorfl/fl and RaptoraKO were treated with vehicle or 2mg/kg
rapamycin for 2 weeks. (A) plasma cholesterol, (B) plasma TG and (C) plasma NEFA
from mice fasted overnight and refed for 4 hours (n=4). Compared to rapamycin treated
groups, *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 3-3. Adipocyte-specific ablation of mTORC2 elevates plasma lipids upon
refeeding.
(A) Western blot for Rictor in IWAT, EWAT, BAT and liver. (B) Body weight with age of
male RictoraKO compared to Rictorfl/fl (n=14). (C) Tissue weights from 5-month-old males.
(D) Plasma cholesterol, (E) plasma TG and (F) Plasma NEFA after an overnight fast and
refed (n=5). 10-week-od Rictorfl/fl and RictoraKO male mice were treated with vehicle or
2mg/kg rapamycin for 2 weeks. (G) Plasma cholesterol and plasma TG from random fed
mice after 2 weeks of rapamycin treatment (n=8-10). Data presented as mean ± s.e.m.
(B-F) *p < 0.05, **p < 0.01, ***p < 0.001. (G) Compared to rapamycin treated groups, *p
< 0.05, **p < 0.01, ***p < 0.001.
IWAT

A

EWAT

Rictor aKO

WT

Liver

BAT

Rictor aKO

WT

Rictor aKO

WT

WT

Rictor aKO

Rictor
!-Actin

B

C

25
20
15

Rictorfl/fl
RictoraKO

10
5
0

3

4

5

6

7

8

9

10

11

5
4
3
2
1
0

12

IWAT

Age (weeks)

E
✱✱✱

100

✱✱

75
50
25
0

Plasma Lipids (mg/dL)

G

Plasma TG (mg/dL)

Plasma Chol (mg/dL)

125

Fasted

250

F

✱✱

200
150
100
50
0

Refed

EWAT

Plasma NEFA (mEq/L)

D

Fasted

RictoraKO
p=0.05

6

% Body Weight

Body Weight (g)

30

Rictorfl/fl

Refed

BAT

Liver

2.0

1.5

✱✱

1.0

0.5

0.0

Fast

Refed

300
✱✱

250
✱

200

✱

✱✱✱

RictoraKO + Vehicle

150

Rictorfl/fl + Rapa

100

Rictorfl/fl + Vehicle

50

RictoraKO + Rapa

0

TG

Chol

91

Figure 3-4. Rapamycin treatment further increases plasma lipids in adiposespecific mTORC1 and mTORC2 KO mice.
10-week-old Raptor-RictoraKO mice were fasted overnight and refed and treated with
2mg/kg rapamycin for 2 weeks. (A) Body weight, (B) blood glucose, (C) plasma
cholesterol, (D) plasma TG and (E) plasma NEFA of Raptor-RictoraKO mice compared to
floxed littermates (n=4) prior to start of rapamycin treatment. (F-H) Plasma cholesterol,
TG and NEFA after 2 weeks of rapamycin. Data presented as mean ± s.e.m. *p < 0.05,
**p < 0.01, ***p < 0.001.
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Figure 3-5. Genetic inhibition of lipolysis reverses lipid phenotypes of adiposespecific mTORC1 KO treated with rapamycin.
10-week-old male mice were fasted overnight and refed for 4 h prior to collection of
EWAT for lipidomics. (E) Total ion counts for NEFA, monoacylglycerols (MG),
diacylglycerols (DG), triglycerides (TG) (n=3-5). 8-week-old female mice were treated
with vehicle or 2mg/kg rapamycin for 2 weeks. (B) Refed plasma cholesterol, (C) plasma
TG and (D) plasma NEFA (n=3-5). Data presented as mean + s.e.m. *p < 0.05, **p <
0.01, ***p < 0.001.
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Figure 3-6. General mechanism for the widespread effects of Raptor deletion on
lipid metabolism.
10-week-old RaptoraKO mice were treated with vehicle or 2mg/kg rapamycin for 2 weeks.
(A) FPLC TG and cholesterol lipoprotein profiles of pooled plasma from random red mice
(RaptorakO n=10, RaptoraKO + rapa n=6). (E) Plasma cholesterol AUC and (F) plasma TG
AUC. For comparison, the control and rapamycin treated C57BL/6 mice plasma
cholesterol and TG AUC is shown. Data presented as a single value
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Supplementary Figure 3-1. Rapamycin treatment further increases lipoprotein
lipids in adipose-specific mTORC1 KO.
4-month-old RaptoraKO mice were treated with vehicle or 2mg/kg rapamycin for 2 weeks.
(A) FPLC TG and cholesterol lipoprotein profiles of pooled plasma from random red mice
(RaptorakO n=10, RaptoraKO + rapa n=6). (E) Plasma cholesterol AUC and (F) plasma TG
AUC. For comparison, the control and rapamycin treated C57BL/6 mice plasma
cholesterol and TG AUC is shown. Data presented as a single value.
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4.1 Summary of Key Findings
mTORC1 and mTORC2 in adipose tissue, in addition to other metabolic tissues, are
known to influence lipid metabolism through multiple pathways. However, the specific
cause of hyperlipidemia induced by rapamycin treatment in vivo remains undetermined.
Here we show that loss of mTORC1 and mTORC2 in adipocytes is sufficient to cause
hypertriglyceridemia. Both genetic mouse models displayed increased refed plasma
cholesterol, triglycerides and NEFA levels. The increase in plasma NEFA and TG
phenotypes of both RaptoraKO and RictoraKO mice is dependent on the feeding state,
providing an explanation for conflicting reports on the effect of rapamycin on NEFA.
Other than hyperlipidemia, additional adipose lipid metabolism effects in our RictoraKO
were not investigated.
Much of this work focused on the role of mTORC1 signaling in adipose. RaptoraKO mice
have decreased LPL gene expression, a small decreased in the LPL activity in vivo and
intracellularly from adipose tissue. In addition, these mice had delayed clearance of
circulating triglycerides. We were able to determine that hepatic production of TG-rich
lipoproteins is not a factor contributing to hypertriglyceridemia in our RaptoraKO mice.
In our RaptoraKO, we did not observe a significant increase in ATGL protein expression in
adipose, yet genetic deletion of ATGL in adipocytes is sufficient to normalize refed NEFA
and TG levels and restored TG clearance without correcting Lpl gene expression. we
showed that stimulated lipolysis in adipose tissue using a b-adrenergic agonist delayed
TG clearance during an oral fat tolerance test. Mechanistically, this work shows defects
in adipose mTORC1signaling induced hypertriglyceridemia is driven mainly by
unrestrained lipolysis in the fed state, which likely interferes lipoprotein lipase activity.
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In this study, we hypothesized that inhibition of adipose mTORC1 changes expression
levels of two key lipid metabolism proteins, C/EBPa and perilipin, leading to
hypertriglyceridemia. We showed that both gene and protein expression were decreased
in RaptoraKO mice, and these mice fail to phosphorylate perilipin upon stimulation of
lipolysis.
The effects of rapamycin on lifespan extension are dose dependent (Bitto et al., 2014;
Miller et al., 2014). Therefore, we used a lower dose that has been shown to extend
lifespan and mice treated with this dose of rapamycin developed hyperlipidemia, which
includes increases in plasma cholesterol, TG, NEFA, phospholipids and in the lipid
content of the different lipoproteins. Most importantly, while deletion of either or both
mTOR complexes in adipose tissue does not elevate plasma TG levels in the fasted
state, rapamycin treatment does.
We successfully show that increased lipolysis with deletion of mTORC1 in adipose
tissue induces hypertriglyceridemia. This study also reports a similar effect with
rapamycin. Using a GPR81 agonist to suppresses adipocyte lipolysis in rapamycin
treated mice, plasma TG levels were normalized after refeeding.
We hypothesized that loss of mTOR signaling in adipose tissue mediates the effects of
rapamycin treatment. Plasma lipids were comparable between rapamycin treated mice
and our RaptoraKO mice and RictoraKO mice. However, when treated with rapamycin, our
RaptoraKO mice, RictoraKO mice and Raptor-RictoraKO mice had an additional increase in
plasma lipids. The additional increase in lipids seen in RaptoraKO mice treated with
rapamycin was prevented with genetic inhibition of lipolysis (ATGL-RaptoraKO). However,
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this did not restore levels comparable to wildtype or ATGLaKO mice treated with
rapamycin, which rapamycin did not increase lipid levels in these mice.
4.2 Implications of impaired mTOR in adipose tissue
It is evident that the adipose tissue is a far more complex tissue than original described
as simply a storage site for excess energy. The integrative responses and lipid
regulation within adipocytes can impact metabolic homeostasis. Biological pathways
related to adipogenesis, insulin signaling, lipolysis, esterification, and lipogenesis within
adipose tissue are implicated as important pathways influencing whole body
homeostasis. Both mTOR complexes have been implicated in regulating these
pathways, but mainly through unknown mechanisms. Alterations in any part of these
pathways ultimately alter the lipid storage of adipose tissue. This leads to excessive
circulating levels of fatty acids and ectopic accumulation in non-adipose tissues, such as
liver and muscle, which is known to cause metabolic abnormalities. Excessive
mobilization of fatty acids into the systemic circulation is responsible for inducing
hyperlipidemia, lipodystrophy and insulin resistance.
Recent studies have reported that rapamycin can inhibit the transactivation of several
transcription factors such as peroxisome proliferator-associated receptor-gamma
(PPARγ) and CCAAT-enhancer-binding proteins (C/EBP), which play key roles in lipid
metabolism and it can change the expression of key enzymes required for fatty acid
uptake and triglyceride synthesis in adipose tissue (Houde et al., 2010; Soliman et al.,
2010). Adipose-specific C/EBPa KO mice develop lipodystrophy earlier in life than our
RaptoraKO mice, however a decrease in CEBPa transcriptional activity could explain both
the lipid phenotype and the development of lipodystrophy. (Chatterjee et al., 2011). As
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previously mentioned, Perilipin is a target of C/EBPa transcriptional control. Perilipin
adipose KO mice have a comparable phenotype to our RaptoraKO of a decrease in
adiposity, consistent with perilipin functioning to protect the lipid droplet from basal lipase
activity of ATGL (Tansey et al., 2001). Additionally, without adipose Perilipin, CGI-58 is
readily available to co-activate ATGL, further increasing lipolysis. In addition, adipocytes
deficient in perilipin have a blunted response to isoproterenol stimulation of lipolysis
(Kim, S. J. et al., 2016). Therefore, this results from this work suggest that the decreased
levels of the perilipin protein itself on the lipid droplet may account for the unrestrained
lipolysis in the refed state and the lack of protein results in decreased phosphorylation
and thus stimulation of lipolysis as seen by decreased plasma NEFA in the fasting state.
In the fed state, intracellular adipose lipase activity is low, and the direction of NEFA
transport is inward, promoting efficient uptake of LPL-generated fatty acids. Presumably,
the vast majority of these fatty acids taken up by adipose tissue are directed toward
esterification and ultimately triglyceride storage. Efficient storage of dietary fat requires
adequate suppression of adipose tissue lipolysis, which typically depends on the
antilipolytic effects of the increased insulin concentrations that are observed after
refeeding. Abnormally high NEFA releases in adipose tissue could contribute to
increased VLDL triglyceride production by raising postprandial portal vein NEFA
concentration (Lewis, 1999; Miles et al., 2005). In addition to insulin’s suppression of
adipose lipolysis, insulin activates LPL transcriptionally and its secretion to the capillary
endothelium (Wang, H. & Eckel, 2009). While it is well established that insulin regulates
mTORC1 activity, mTORC1 seems to regulate LPL activity through other mechanisms
intendent of insulin. We do see a decrease in LPL mRNA in white adipose tissue,
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consistent with the insulin dependent regulation on LPL transcription. A significant
decrease in post-heparin LPL activity was observed in patients showing sirolimusinduced hypertriglyceridemia and that gene expression was decreased by 60% in the
presence of rapamycin (Hoogeveen et al., 2001; Kraemer et al., 1998). In addition,
treatment with rapamycin associated with a 92% increase in apolipoprotein CIII, which is
a potent inhibitor of LPL (Morrisett et al., 2002). Thus, all these data indicate that mTOR
inhibitors are likely to decrease LPL activity and thus to reduce the catabolism of
triglyceride-rich lipoproteins leading to hypertriglyceridemia. However, the effect on
secretion and hydrolysis activity with loss of mTORC1 signaling is not alter in our study
and the clinical assessment of rapamycin was performed in the fasted state, where LPL
activity is typically suppressed in adipose. Instead, the indirect effects of unrestrained
lipolysis in the fed state clearly inhibits the physiological role of LPL to remove
triglycerides from lipoproteins. It has long been appreciated that NEFA can suppress
LPL through multiple mechanisms, including product inhibition, displacement of the
active enzyme from the endothelium, and preventing its interaction with activating factors
such as ApoC-II (Amri et al., 1996; Gordts et al., 2016; Peterson, J. et al., 1990; Saxena
et al., 1989). As demonstrated by the use of stimulating NEFA releases from adipose
tissues during a triglyceride clearance assay, the increase concentrating of circulating
NEFA decrease the rate of clearance of TG from the blood for proper storage in adipose
tissue. This key finding, which has been shown by a few previous groups, has not been
extensively studied in the clinical setting. In some cases of hypertriglyceridemia,
inhibiting adipose lipolysis may aid in treatment for patients. In the context of anti-ageing
agents or treatments that target mTORC1, development of inhibitors need to be assed
for the effect on adipose lipolysis.
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One factor that can contribute to impaired lipid clearance is lipodystrophy, in which there
is less total adipose tissue. This may contribute to the worsening of mTORC1
phenotypes with age, but we do not believe it drives the basal phenotype because we
see the development of hypertriglyceridemia prior to the onset of lipodystrophy. We do
believe that the increased lipolysis leads to lipodystrophy in our mice. Mice with an
inability to maintain adipose-depot stores have profound changes in their systemic
physiology, exhibiting similar effects as human patients with lipodystrophy (Garg et al.,
2004). The failure to maintain adipose stores due to this enhanced lipolysis
progressively decreases adipose mass. However, when downstream factors in the
insulin signaling cascade are targets, mild lipodystrophy phenotypes are observed with
surprisingly profound effects on insulin sensitivity. Although insulin resistance was not
the focus of this study, other groups have shown that ablation of the mTORC1’s function
also leads insulin intolerance and progressive lipodystrophy. This suggests that
mTORC1 might be a critical downstream target of insulin signaling in the maintenance of
adipose tissue (Lee, P. L. et al., 2016; Liu, D. et al., 2016). However, this group did not
assess insulin tolerance prior to the onset of lipodystrophy. Therefore, it remains unclear
whether unrestrained lipolysis leads to lipodystrophy or if insulin intolerance is the cause.
In addition, the effect of increased lipolysis most likely leads to the insulin phenotype of
Raptor adipose KO mice, suggesting a possible mechanism that increased lipolysis may
lead to insulin resistance which causes lipodystrophy.
In mTORC2 adipose KO mice, insulin resistance and a progressive lipodystrophy is also
seen (Tang et al., 2016). This mouse model also exhibits defects in glucose uptake,
regulation of de novo lipogenesis, and an inability to fully suppress lipolysis in response
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to insulin (Tang et al., 2016). Suggesting that the role of mTORC2 in rapamycin’s insulin
side effects may play a role. However, the inhibition of mTORC1 is mainly responsible
for the lipodystrophy induce by excess lipolysis, as reverse the lipolysis phenotype in
RaptoraKO mice prevents the loss of adipose mass.
4.3 Implications of rapamycin on adipose mTOR signaling
The pathophysiology of mTOR inhibitor-induced dyslipidemia is not yet totally clear. In
vitro studies have shown that mTOR inhibition by rapamycin increases fatty acids in
hepatocytes oxidation while decreasing fatty acid flux into anabolic storage pathways
and skeletal muscles (Brown, N. F. et al., 2007; Busaidy et al., 2012; Sipula et al., 2006).
In addition, several studies have shown that rapamycin decreases the gene expression
of lipogenic enzymes such as acetyl-CoA carboxylase, fatty acid synthase, and stearoylCoA desaturase (Brown, N. F. et al., 2007; Mauvoisin et al., 2007; Peng, T. et al., 2002).
The work from this study and previous studies indicate that mTOR inhibitors are likely to
decrease LPL activity and thus to reduce the catabolism of triglyceride-rich lipoproteins
leading to hypertriglyceridemia. However, must studies conclude that the effect on LPL
is a direct inhibition of activity by apolipoproteins or by deceased expression through the
insulin pathway. One study did find no significant differences in post heparin LPL activity
with rapamycin and concluded that rapamycin on lipid metabolism is most likely not
mediated by LPL (Hoogeveen et al., 2001). However, these clinical studies on patients
treated with rapamycin are all performed in the fasted state. In 2007, Kimak et al. did a
fasting and refeeding study in renal transplant patients but not focused on specifically on
the use of rapamycin as the immunosuppressant (Kimak et al., 2007). This study found a
~40 mean increase in plasma triglycerides from fasting to refeeding. This is in line with
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our results, that the refed state is important when measuring lipids in the context of
rapamycin inhibition of adipose mTOR signaling.
While most of the beneficial effects of rapamycin in regards to health and longevity are
due to inhibition of mTORC1, many of the negative side effects are mediated through the
off-target inhibition of mTORC2 with rapamycin. Therefore, it is believed that the side
effects of rapamycin and rapalogs can be avoided by selectively inhibiting mTORC1
signaling (Lamming, 2014). In 2019, DL001, a rapamycin analog that has greater
selectivity for mTORC1 compared to rapamycin, selectively inhibits mTORC1 both in in
vitro and in vivo and does not inhibit mTORC2. Schreiber et al. shower that DL001,
unlike rapamycin, does not affect glucose or lipid homeostasis. DL001 did not increase
blood levels of cholesterol, triglycerides, and free fatty acids. In white adipose tissues,
which rapamycin increases ATGL protein expression, DL001-treated animals only had
an 16% increase in ATGL. Similarly to our data, this group concluded that mTORC1
regulates lipolysis in adipose tissue, however, they suggest that this effect is not
sufficient to cause hyperlipidemia induced by rapamycin. This study, much like many
clinical studies, only examines fasted lipids. While rapamycin does increase fasting
triglycerides, which is independent of adipose mTORC1 according to our data,
triglyceride levels are increases more substantially upon feeding. Adipose mTORC1
signaling is significantly decreased during fasting. Therefore, all studies examining
rapamycin or mTOR inhibitors in the fasted state are excluding potential results due to
the influence of the adipose tissue on whole body lipid homeostasis, specifically the
refed regulation on intracellular lipolysis and LPL.
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The study on DL001 was performed on mice after 5 weeks of treatment, which is longer
than most clinical studies. The results indicate that even if this compound increases
refed adipose lipolysis and plasma triglycerides as in our study, the plasma levels of
these lipids are normalized upon fasting. However, as previously discussed, long term
increase in lipolysis can lead to lipodystrophy and insulin resistance, leading to potential
complications with long term use of DL001 or other compounds. It remains unlikely that
compounds that inhibit mTOR signaling can be used clinically for a long term without an
additional therapeutic agent, such as lipolysis inhibitors. Although niacin has been used
clinically to suppress postprandial hypertriglyceridemia in humans, may side effect occur
after long term use, such as flushing (Montserrat-de la Paz et al., 2018; Usman et al.,
2012). In this study, the use a GPR81 agonist, which inhibits lipolysis specifically in
adipose tissue, successfully suppressed NEFA release from adipose tissue and
sufficiently normalize plasma TG in rapamycin-treated mice. The use of rapamycin,
rapalogs or other mTOR inhibitors that increase lipolysis in conjunction with a GPR81
agonist may be sufficient to improve lifespan while eliminating hyperlipidemia for long
term use in humans. However, long term side effects of the GPR81 agonists have yet to
be explored.
4.4 Limitations of This Study
In chapter 3, appropriate parameters, male mice less than 12 weeks old were fasted and
refed, were used for all experiments. However, there are a few limitations of this study
that must be addresses from chapter 4.
Although multiple cohorts of RaptoraKO mice less than 12 weeks old were treated with
rapamycin, random fed plasma lipids results were variable from cohort to cohort. We
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suspect this discrepancy is due to the later observation of feeding status on plasma
lipids in RaptoraKO mice. For Figure 3.2, mice older than 12 weeks of age were used to
measure fasted and refed plasma lipids with rapamycin treatments. Therefore, it should
be noted that those mice have developed lipodystrophy prior to the start of rapamycin
treatment.
While RictoraKO mice do not develop lipodystrophy with age, it should be noted that the
mice used in Figure 3.3 A-F are around 5 months old. In Figure 3.3, plasma lipids were
measured in the random fed state. Although only results from one cohort is graphed, this
experimental design was repeated with multiple cohorts. Due to progressively poor
breeding with the Rictorfl/fl line that occurred, we were unable to obtain a cohort with
enough mice to measure fasted and refed plasma lipids with rapamycin treatments.
Similarly to the breeding issues with the Rictorfl/fl line, the Raptor-Rictorfl/fl line failed to
produce litter sizes with enough mice of each genotype for experiments. In Figure 3.4,
only one cohort of Raptor-RictoraKO mice were treated with rapamycin and no mice were
available for vehicle treated groups. Therefore, the cohort used in Figure 3.4 A-E is prerapamycin treatment. Figure 3.4 F-H is 2 weeks post-treatment of the same cohort. Due
to the lack of vehicle treatment, the tissues weights and downstream signaling (both
gene and protein expression) phenotypes of Raptor-RictoraKO mice independent of
rapamycin were not investigated.
4.5 Future Directions
Although this study provides new understanding of the influence of mTOR signaling in
adipose tissue on lipid homeostasis and the development of hypertriglyceridemia with
rapamycin, there are questions that still remain unanswered. In regards to rapamycin
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treatment: 1. What are the effects on plasma TG clearance and hepatic TG secretion? 2.
What are the effects on LPL activity in both the fasted state and refed state? 3. How do
these effects of rapamycin treatment compare to the changes in RaptoraKO? These
questions can be answered by performing oral fat tolerance tests, hepatic TG secretion
assay and by measuring fasting and refed LPL activity (gene expression, intracellular
LPL activity and post heparin plasma LPL activity in mice treated with rapamycin. We
can determine if production or degradation of plasma TG results in hyperlipidemia.
These results would also identify if the results from our RaptoraKO mice are rapamycin
sensitive or in sensitive effects. It is hypothesize that rapamycin will delay TG clearance
as an result of mTOR inhibition in the adipose and that the cause of increased fasted
plasma TG, which is independent of mTORC1 in adipose tissue, is not due to increased
hepatic TG secretion but rather a defect in muscle LPL activity. Performing these
experiments on RictoraKO mice can also improve our understanding of adipose mTORC2
signaling on lipid homeostasis.
The known downstream signaling of mTORC1 and mTORC2 in adipose tissue does not
adequately explain the detrimental effects on lipid metabolism. Therefore, a better
understanding of the signaling pathways is needed. Using mass-spectrometry-based
phosphoproteomics we can create an extend mTOR signaling pathway, allowing
identification of potential targets that mediate lipid metabolism regulation by adipose
mTOR. Phosphoproteomics has been used to investigate the roles of mTOR complexes
in liver, but in the adipose tissue, this technique has generally lagged. This is in part due
to the difficulty of sufficiently removing fat from the tissue. Unwanted cellular material,
such as lipids and genomic DNA, results in signal suppression. Removal of lipids
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provides a cleaner, clearer spectrum of peptides. Proteins embedded in lipid bilayers
require efficient and complete digestion, which remains a challenge and an area for
continuing methodological development (Shaik et al., 2016). As adipose tissue is mainly
comprised of lipids, a successful and universal method for phosphoproteomics on white
adipose tissue has yet to be established. Phosphoproteomics will allow an unbiased and
quantitative analysis to determine new targets downstream of mTOR signaling in
adipose tissue. We have collaborated with the Garcia lab here at Penn to establish a
robust method for performing mass spectrometry on this tissue. Our ongoing
collaboration with Ben Garcia’s mass spectrometry group has already established a
robust method for performing mass spectrometry on white adipose tissue in which that
we can detected several thousand distinct phosphosites. By treating RaptoraKO mice and
RictoraKO with insulin, which regulates lipolysis and LPL in adipose, or CL316,243, which
regulates independently from insulin signaling and with different downstream effects, we
can identify the targets of lipid metabolism that are regulated by mTOR signaling. In
addition, performing phosphoproteomics on white adipose tissue from rapamycin treat
mice will identify rapamycin sensitive and insensitive targets that are downstream of
either mTOR complex.
Not only do this work expand our understanding of the role of adipose mTOR complexes
in the propagation of hyperlipidemia, but also provides insight on the impact adipose
tissue lipid metabolism has on the development of lipodystrophy and insulin resistance.
The results from this study and the future work has the potential of revealing new biology
and potentially new therapeutic strategies to combat hyperlipidemia associated with
rapamycin treatment, allowing therapeutic use as an anti-ageing agent in humans, as
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well as adipose induce metabolic dysfunction. thus informing our understanding of the
role of adipose mTOR complexes in the propagation of insulin resistance from the
adipocyte to the muscle and liver.
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CHAPTER 5: Materials and Methods
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5.1 Animals and Treatments
All experiments were approved by the Institutional Animal Care and Use Committee at
the University of Pennsylvania. Adipocyte-specific raptor knockout mice (RaptoraKO) were
generated by crossing raptor floxed mice containing loxP sites flanking exon 6 of the
targeted Rptor (B6.Cg-Rptortm1.1Dmsa/J) with mice containing the Adipoq-Cre BAC
transgene express Cre recombinase under control of the mouse adiponectin (Adipoq)
promoter/enhancer regions (B6.FVB-Tg(Adipoq-cre)1Evdr/J) (Eguchi et al., 2011;
Sengupta et al., 2010). ATGL-RaptoraKO were generated by crossing ATGLfl/fl mice
containing loxP sites flanking exons 2-7 of the Pnpla2 gene (B6N.129S-Pnpla2tm1Eek/J)
(Sitnick et al., 2013). with Raptorako mice. To generate adipose specific rictor knockout
mice, we crossed mice in which the rictor gene were flanked by loxP sites (Rictorfl/fl) to
mice expressing cre recombinase under the control of the adipose specific adiponectin
gene promoter (RictoraKO) (Guertin et al., 2009). The following primer sequences were
used for genotyping: Rptor: forward, 5’-CTCAGTAGTGGTATGTGCTCAG-3’; reverse,
5’-GGGTACAGTATGTC AGCACAG-3’. Pnpla2: forward 5’GAGTGCAGTGTCCTTCACCA-3’; reverse 5’-ATCAGGCAGCCA CTCCAAC-3’. Rictor:
forward 5’-GACACTGGATTACAGTGGCTTG-3’; reverse 5’ACTGAATATGTTCATGGTTGTG-3’. Adipoq-Cre: forward 5'ACCTCCTGGGAGAGTGAGGGC-3'; reverse 5'-GCATCGACCGGTAATGCAGGC-3'.
Age-matched floxed mice (Raptorfl/fl, Raptorfl/flATGLfl/fl, ATGLfl/fl), RaptoraKO, ATGLaKO and
ATGL-RaptoraKO male mice were studied between 10 weeks to 12 weeks of age unless
otherwise stated. For fasting and refeed experiments, mice were fasted overnight and
refed for 4 h. For stimulating lipolysis, mice were injected intraperitoneally with 1 mg/kg
b3-adrenergic receptor agonist, CL316,243 (Sigma-Aldrich). For rapamycin treatment,
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mice were intraperitoneally injected with 2 mg/kg rapamycin (LC Laboratories) in 0.25%
PEG400/Tween80 daily for 2 weeks. To suppress lipolysis, mice were intraperitoneally
injected with 100 mg/kg GPR81 Agonist, 3Cl-5OH-BA (Sigma-Aldrich), at the beginning
of refeeding. Mice were sacrificed by cervical dislocation after an overnight fast and 4 h
of refeeding.
5.2 Western Blot
Tissue samples were lysed in RIPA buffer supplemented with 10 µL/mL Halt™ Protease
and Phosphatase Inhibitor Cocktail (ThermoFisher, 78440), and homogenized using a
TissueLyser II (Qiagen). Lysates were incubated with gentle rocking for 30 min at 4oC
then centrifuged 12,000 g for 20 minutes at 4oC twice, transferring the supernatant.
Protein concentration was determined by BCA Assay (Pierce). 12-20 µg of total protein
was loaded onto sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDSPAGE) 4-15% Tris-Glycine gradient gels or 10% resolving gels (Bio-Rad) and
subsequently transferred to PVDF membranes (Bio-Rad). Membranes were blocked with
either 3% BSA (for phospho-proteins) or with 3% non-fat dry milk in TBST (50 mM Tris,
pH 7.6, 150 mM NaCl, 0.1% tween 20) and incubated overnight at 4 °C in blocking
solution with the following primary antibodies at 1:2000: Raptor (Cell Signaling, 2280),
ATGL (Cell Signaling, 2138), pAkt Ser473 (Cell Signaling, 9271), Akt (Cell Signaling,
9272), pS6 Ser240/Ser244 (Cell Signaling, 2215), S6 (Cell Signaling, 2212), p4EBP1
Ser65 (Cell Signaling, 9451), 4EBP1 (Cell Signaling, 9452), Rictor (Cell Signaling,
2140), Perilipin (NB110-40760), CEBPa (Santa Cruz, sc-61) and pPerilipin Ser522 (Vala
Sciences, 4856). Secondary HRP conjugated antibodies (Jackson ImmunoResearch
Laboratories, Inc.) were used at 1:10,000 in TBST and 1:10,000 for HRP conjugated B112

actin (Abcam, 9620272). Immunolabeling was detected using the PICO Plus or Femto
ECL reagent (Pierce). Band densities were quantified using Image Lab version 5.2.1 and
band intensities were normalized to b-actin (Bio-Rad).
5.3 Plasma Lipid Analysis
Blood was collected from the tail veins of mice in Microvette CB300 LH K2E tubes
(Sarstedt). For retro orbital bleeding, mice were first anesthetized with isoflurane. Blood
was collected into Fisherbrand Micro Blood Collecting Tubes, Natelson; Ammonium
heparin. Plasma was analyzed for cholesterol using the InfinityTM Cholesterol Liquid
Stable Reagent (ThermoFisher, TR13421), triglycerides using the InfinityTM Triglycerides
Liquid Stable Reagent (ThermoFisher, TR22421), non-esterified fatty acids using the
Free Fatty Acid Kit (Wako, HR series NEFA-HR(2)) and glycerol using the Free Glycerol
Reagent (Sigma, F6428) according to the manufacturer’s instructions. For plasma lipid
panels on rapamycin treatment mice, lipids were measured using enzymatic assays as
described (Amar et al., 1998; Dugi et al., 2000; Nong et al., 2003). HDL-cholesterol
(HDL-C), was determined after precipitation of ApoB-containing lipoproteins with dextran
sulfate (Bayer Corp., Tarry- town, NY), and then subtracted from total cholesterol (TC) to
obtain non-HDL cholesterol (Gonzalez-Navarro et al., 2004). Lipoproteins were analyzed
by fast-protein liquid chromatography (FPLC), using 150 µl of pooled plasma as
described (Amar et al., 1998; Dugi et al., 2000; Gonzalez-Navarro et al., 2004).
5.4 Tissue Triglycerides
Tissue pieces were homogenized in a 20x volume of 2:1 chloroform:methanol then
incubated at room temperature with agitation for 3 hours. After addition of 0.9% NaCl,
samples were vortexed and centrifuged (2000 rpm, 10 minutes). The lower organic
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phase was collected and dried under N2 gas. TG content was measured using the
InfinityTM Triglycerides Liquid Stable Reagent (ThermoFisher, TR22421) and normalized
to starting tissue weight.
5.5 Hepatic TG Secretion
Mice were either fasted for four hours or overnight and refed for 4 hours and injected
intraperitoneally with 1 g/kg body weight Pluronic F-127 (P-407) (BASF, 30085239) in
PBS. Blood was drawn at indicated time points after P-407 injection. 2 mL/kg blood was
collected at each time point. Plasma triglycerides and NEFA were measured. For
CL316,243 treatment, mice were injected 1 hour post P-407 injection.
5.6 Oral Fat Tolerance Test
Mice were fasted overnight and fed 2 mg/g body weight Olive oil (Acros, 8001-25-0)
through oral gavage. Approximately 50 µL of blood was collected at baseline (prior to
gavage) and at indicated time points. Plasma triglycerides and NEFA were measured.
For CL316,243 treatment, mice were injected 1 hour post gavage.
5.7 Quantitative Real Time RT-PCR analysis
Total RNA was extracted using TRIzol. RNA was used to generate cDNA with the High
Capacity Reverse Transcription Kit (Applied Biosystems). Reactions were run on a 7900
HT Fast Real-Time PCR System (Applied Biosystems) using SYBR Green Master Mix
(Applied Biosystems) with results normalized to Tbp. Primer sequences are listed in
Table 5.1.
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5.8 Post Heparin Plasma LPL
Mice were either fasted for four hours or overnight and refed for 4 hours then injected
with 0.5 units/g body weight (4 µL/g of 125 units/ml in sterile PBS) heparin (Sagent,
25021-400-10) through the tail vein. Mice were bleed retro-orbitally at baseline and then
10 minutes after heparin injection. Plasma LPL activity was assayed using the
Lipoprotein Lipase (LPL) Activity Assay Kit (Fluorometric) (Cell Biolabs, STA-610)
according to the manufacturer’s instructions.
5.9 Tissue LPL Activity
Tissues (IWAT, EWAT, BAT, skeletal muscle) were assayed using the Lipoprotein
Lipase (LPL) Activity Assay Kit (Fluorometric) (Cell Biolabs, STA-610) according to the
manufacturer’s instructions.
5.10 Lipidomics
Liquid chromatography mass spectrometry (LC-MS) analysis of lipids from mice adipose
samples was performed as follows. About 30 mg of frozen tissue samples were weighed
and then pulverized in a CryoMill (Retsch, Germany) with stainless ball at liquid nitrogen
temperature. 1 mL 0.1M HCl in 50:50 methanol:H2O was added to the tissue powder,
vortexed for 10 seconds, and let sit in -20°C freezer for 30 min. Then 0.5 mL of
chloroform was added to the mixture and vortex to mix well, and let sit on ice for 10 min.
Samples were centrifuged at 13200 rpm for 10 min and the chloroform phase at bottom
was transferred to a glass vial as the first extract using a Hamilton syringe. 0.5 mL
chloroform was added to the remaining material and the extraction was repeated to get
the second extract. The combined extract was dried under nitrogen flow and re115

dissolved in solvent of 1:1:1 methanol:chloroform:2-propanol using a ratio of 1 mL of
solvent per 10 mg of initial tissue weight. Fatty acids and lipids were analyzed on a Q
Exactive Plus mass spectrometer coupled to vanquish UHPLC system (ThermoFisher
Scientific, San Jose, CA). Each sample was analyzed twice using same LC gradient but
different ionization mode on mass spectrometer to cover both positive charged and
negative charged species. The LC separation was achieved on an Agilent Poroshell 120
EC-C18 column (150 x 2.1 mm, 2.7 μm particle size) at a flow rate of 150 μL/min. The
gradient was 0 min, 25% B; 2 min, 25% B; 4 min, 65% B; 16 min, 100 %B; 20 min, 100%
B; 21 min, 25% B; 27 min, 25% B (Papazyan et al., 2016). Solvent A is 1mM Ammonium
acetate + 0.2% acetic acid in Water:Methanol (90:10). Solvent B is 1mM Ammonium
acetate + 0.2% acetic acid in Methanol:2-propanol (2:98). For all experiments, 5 µl of
extract was injected with column temperature set to 60 °C. The Q-Exactive Plus mass
spectrometer was operated scanning m/z 70-1000 with a resolution (at m/z 200) of
140,000. MS parameters are as follows: sheath gas flow rate, 28 (arbitrary units); aux
gas flow rate, 10 (arbitrary units); sweep gas flow rate, 1 (arbitrary units); spray voltage,
3.3 kV; capillary temperature, 320°C; S-lens RF level, 65; AGC target, 3E6 and
maximum injection time, 500 ms. Data analyses were performed using MAVEN software
which allows for sample alignment, feature extraction and peak picking (Melamud et al.,
2010). Exacted ion chromatogram for each metabolite was manually examined to obtain
its signal, using a custom-made metabolite library.
5.11 Ex vivo Lipolysis
Epididymal adipose tissue was isolated from random fed mice. Each fat pad was cut into
equal size pieces and were placed in a 96 well plate containing 150 µL of phenol-free
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DMEM media (Thermo Fisher Scientific, 21063) supplemented with 2% fatty acid free
bovine serum albumin (BSA) (Sigma, A8806). For mTORC1 inhibition, 500nM rapamycin
was added to media. For ATGL inhibition, 100µM ATGListatin (MedKoo, 510273) was
added to media. Tissue pieces were pre-incubated for 60 min. For basal lipolysis, tissue
pieces were incubated in new media for 60 minutes. For stimulated lipolysis tissue
pieces were pretreated with 1µM CL316,243 for 30 min. To detect release of NEFA,
tissue pieces were then placed in a new well with same media for 60 min. Media was
measured for NEFA and normalized to protein. To determine protein concentration, each
piece was incubated with 1mL chloroform for 60 minutes. Then the tissue was
transferred and lysed in 0.3M NaOH containing 0.1% sodium dodecyl sulfate (SDS) and
incubated overnight at 65oC. Protein concentration was determined by BCA Assay.
5.12 Statistical analysis
All data are presented as mean + SEM and analyzed using Prism version 8 (Graphpad).
Statistical significance was determined using unpaired two-tailed Student’s t-test for
single comparisons and one-way or two-way ANOVA followed by Tukey posthoc test for
multiple comparisons unless otherwise indicated.
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Table 5-1. Primer Sequences for Quantitative Real Time RT-PCR
Gene

Forward Primer 5'-3'

Reverse Primer 5'-3'

Angptl4

AAGATGCACAGCATCACAGG

ATGGATGGGAAATTGGAGC

Arg1

CCAGGGACTGACTACCTTAAAC

GAAGGCGTTTGCTTAGTTCTG

CD11c

ATGTTGGAGGAAGCAAATGG

CCTGGGAATCCTATTGCAGA

CD45

ATATCGCGGTGTAAAACTCGTC

TAGGCTTAGGCGTTTCTGGAA

CD68

TGCCACAGTTTCTCCCACCA

AAGAGCCCCCTTGGACCTTG

Cgi-58

TGGTGTCCCACATCTACATCA

CAGCGTCCATATTCTGTTTCCA

F4/80

TGGCTGCCTCCCTGACTTTC

CAAGATCCCTGCCCTGCACT

Il-6

TAGTCCTTCCTACCCCAATTTCC

TTGGTCCTTAGCCACTCCTTC

Lpl

ACTCGCTCTCAGATGCCCTA

TTGTGTTGCTTGCCATTCTC

Plin1

AGGCTGTCTCCTCTACCAAA

CCACAGTGTCTACCACGTTATC

Tnfα

CCCTCACACTCAGATCATCTTCT

GCTACGACGTGGGCTACAG

Cebpa

AAACAACGCAACGTGGAGAC

TGTCCAGTTCACGGCTCAG

Tbp

CCCCTTGTACCCTTCACCAAT

GAAGCTGCGGTACAATTCCAG
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